日本臨牀　81/増刊3　新リンパ腫学

出版社： 日本臨牀社
発行日： 2023-03-31
分野： 臨床医学：一般  >  雑誌
ISSN： 00471852
雑誌名：
特集： 新リンパ腫学
電子書籍版： 2023-03-31 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：4～8営業日

22,000 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

22,000 円(税込)

購入する

目次

  • 特集　新リンパ腫学
    　　　―基礎・臨床の最新動向―

    序　文
    1
    I．悪性リンパ腫診療に求められる疾患背景因子の基礎知識
    　1．HTLV-1による成人T細胞性白血病・リンパ腫の発症機構
    　2．小児悪性リンパ腫の病型・臨床病理的特徴
    　3．ウイルス性肝炎における悪性リンパ腫リスク
    　4．HIV関連悪性リンパ腫の発症リスクとメカニズム
    　5．重複悪性リンパ腫の臨床病理的特徴
    　6．自己免疫疾患・慢性炎症と悪性リンパ腫
    　7．リンパ腫発症の遺伝的素因
    　8．臓器移植/造血幹細胞移植とリンパ増殖性疾患
    　9．医原性免疫不全に関連するリンパ増殖症

    II．悪性リンパ腫の分子腫瘍学的異常・病態形成機序
    　1．CLLの発症・病態形成と分子腫瘍学的異常
    　2．LPLの病態形成と分子腫瘍学的異常
    　3．マントル細胞リンパ腫の病態形成と分子腫瘍学的異常
    　4．濾胞性リンパ腫の分子病態
    　5．びまん性大細胞型B細胞性リンパ腫の分子腫瘍学的異常
    　6．血管免疫芽球性T細胞リンパ腫の病態形成と分子腫瘍学的異常
    　7．PTCL- NOSの分子腫瘍学的異常
    　8．成人T細胞性リンパ腫の病態形成と分子遺伝学的異常
    　9．ホジキンリンパ腫の病態形成と分子病態
    　10．Epstein-Barr VirusによるT,NK細胞の腫瘍化のメカニズム
    　11．悪性リンパ腫の病態形成と腫瘍微小環境の分子腫瘍学

    III．悪性リンパ腫の診断概論
    　1WHO分類第5版(2022)の骨格とキーポイント
    　2．臨床医が知っておくべき悪性リンパ腫の病理診断の基本と応用
    　3．悪性リンパ腫の染色体異常　診断法と臨床的意義
    　4．悪性リンパ腫の細胞表面抗原解析　診断の基本と応用
    　5．悪性リンパ腫のFDG-PET/CTによる画像診断と効果判定のエッセンス
    　6．悪性リンパ腫のクリニカル・シーケンス　臨床的意義と展望

    IV．悪性リンパ腫の予後予測因子
    　1．B細胞性リンパ腫の臨床的予後予測指標
    　2．T細胞性リンパ腫の臨床的予後予測指標
    　3．ホジキンリンパ腫の臨床的予後予測指標
    　4．悪性リンパ腫の中枢神経浸潤リスクと治療的アプローチ

    V．病型各論　―疾患概念・疫学・分類・臨床像・診断・治療・予後・話題―
    　1．ホジキンリンパ腫
    　2．Bリンパ芽球性白血病・リンパ腫, 非特異型
    　3．慢性リンパ性白血病/小リンパ球性リンパ腫
    　4．B細胞前リンパ球性白血病
    　5．特異的遺伝子異常を伴うBリンパ芽球性白血病/リンパ腫, 非特定型
    　6．ヘアリーセル白血病
    　7．リンパ形質細胞性リンパ腫・原発性マクログロブリン血症
    　8．節外性粘膜関連リンパ組織型辺縁帯リンパ腫
    　9．節性辺縁帯リンパ腫
    　10．濾胞性リンパ腫
    　11．マントル細胞リンパ腫
    　12．びまん性大細胞型B細胞リンパ腫, 非特定型
    　13．高悪性度B細胞リンパ腫の診断と治療
    　14．B細胞リンパ腫, 分類不能型, びまん性大細胞型B細胞リンパ腫と
    　　　　古典的ホジキンリンパ腫の中間型
    　15．縦隔原発大細胞型B細胞リンパ腫
    　16．血管内大細胞型B細胞リンパ腫
    　17．形質芽球性リンパ腫
    　18．原発性体腔液リンパ腫
    　19．HHV8関連リンパ増殖性疾患
    　20．バーキットリンパ腫
    　21．Tリンパ芽球性白血病・リンパ腫, 非特定型
    　22．T細胞前リンパ球性白血病(T-PLL)
    　23．T細胞大型顆粒リンパ球性白血病
    　24．アグレッシブNK細胞白血病
    　25．成人T細胞白血病・リンパ腫 (ATL)
    　26．未分化大細胞型リンパ腫（ALK陽性、ALK陰性, 乳房インプラント関連）
    　27．血管免疫芽球型T細胞性リンパ腫 (AITL), および その他のT濾胞ヘルパーT細胞リンパ腫
    　28．節外性NK/T細胞リンパ腫・鼻型
    　29．腸管T細胞リンパ腫
    　30．肝脾T細胞リンパ腫
    　31．皮下脂肪織炎様T細胞リンパ腫
    　32．菌状息肉腫・セザリー症候群
    　33．末梢性T細胞リンパ腫, 非特定型
    　34．キャッスルマン病
    　35．TAFRO症候群

    VI．節外リンパ腫の臓器別特徴に基づく診断と治療
    　1．中枢神経系原発リンパ腫
    　2．皮膚リンパ腫
    　3．眼付属器リンパ腫
    　4．眼内悪性リンパ腫
    　5．乳腺リンパ腫
    　6．精巣リンパ腫
    　7．肺リンパ腫・リンパ腫様肉芽腫症・膿胸関連リンパ腫
    　8．消化管リンパ腫
    　9．子宮・卵巣リンパ腫

    VII．悪性リンパ腫に対する新規治療戦略の現状と展望
    　1．B細胞性リンパ腫に対するモノクローナル抗体薬・抗体薬剤複合体
    　2．T細胞性リンパ腫に対するモノクローナル抗体薬・抗体薬剤複合体
    　3．悪性リンパ腫における免疫チェックポイント阻害抗体薬のエビデンスと展望
    　4．成熟B細胞性腫瘍におけるB細胞受容体シグナル標的治療薬と分子病態
    　5．エピジェネティクスを標的とした悪性リンパ腫に対する治療戦略
    　6．悪性リンパ腫に対するBCL-2阻害剤の治療応用のエビデンスと展望
    　7．二重特異性抗体の開発経緯と臨床応用の進歩
    　8．悪性リンパ腫に対するキメラ抗原受容体T細胞療法の現在地と展望
    　9．悪性リンパ腫に対する同種造血幹細胞移植の適応, エビデン, 展望

    VIII．悪性リンパ腫治療における支持療法・患者管理のチップス
    　1．悪性リンパ腫に特徴的な感染対策としての予防投薬・予防接種
    　2．悪性リンパ腫診療における栄養管理
    　3．悪性リンパ腫の免疫化学療法・分子標的治療における腫瘍崩壊症候群対策
    　4．悪性リンパ腫における化学療法誘発性末梢神経障害の診断と対策
    　5．悪性リンパ腫治療と重複がん
    　6．悪性リンパ腫診療における妊孕性温存
    7. その他の合併症（infusion reaction、B型肝炎再活性化、心毒性）の対策

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

[I] 悪性リンパ腫診療に求められる疾患背景因子の基礎知識

P.11 掲載の参考文献
1) Shimoyama M:Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group(1984-87). Br J Haematol 79:428-437, 1991.
 
2) Uchiyama T, Yodoi J, Sagawa K, et al:Adult T-cell leukemia:clinical and hematologic features of 16 cases. Blood 50:481-492, 1977.
PubMed
3) Watanabe T:Current status of HTLV-1 infection. Int J Hematol 94:430-434, 2011.
PubMed
4) Takeda S, Maeda M, Morikawa S, et al:Genetic and epigenetic inactivation of tax gene in adult T-cell leukemia cells. Int J Cancer 109:559-567, 2004.
PubMed
5) Gaudray G, Gachon F, Basbous J, et al:The complementary strand of the human T-cell leukemia virus type 1 RNA genome encodes a bZIP transcription factor that down-regulates viral transcription. J Virol 76:12813-12822, 2002.
PubMed
6) Yoshie O, Fujisawa R, Nakayama T, et al:Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T cells. Blood 99:1505-1511, 2002.
PubMed
7) Nakagawa M, Schmitz R, Xiao W, et al:Gain-of-function CCR4 mutations in adult T cell leukemia/lymphoma. J Exp Med 211:2497-2505, 2014.
PubMed
8) Kataoka K, Nagata Y, Kitanaka A, et al:Integrated molecular analysis of adult T cell leukemia/lymphoma. Nat Genet 47:1304-1315, 2015.
PubMed
9) Yamagishi M, et al:Chronological genome and single-cell transcriptome integration characterizes the evolutionary process of adult T cell leukemia-lymphoma. Nat Commun 12:4821, 2021.
PubMed
10) Yashiki S, Fujiyoshi T, Arima N, et al:HLA-A*26, HLA-B*4002, HLA-B*4006, and HLA-B*4801 alleles predispose to adult T cell leukemia:the limited recognition of HTLV type 1 tax peptide anchor motifs and epitopes to generate anti-HTLV type 1 tax CD8(+) cytotoxic T lymphocytes. AIDS Res Hum Retroviruses 17:1047-1061, 2001.
PubMed
11) Satou Y, Miyazato P, Ishihara K, et al:The retrovirus HTLV-1 inserts an ectopic CTCF-binding site into the human genome. Proc Natl Acad Sci USA 113:3054-3059, 2016.
PubMed
12) Matsuo M, Ueno T, Monde K, et al:Identification and characterization of a novel enhancer in the HTLV-1 proviral genome. Nat Commun 13:2405, 2022.
PubMed
13) Tan BJ, Sugata K, Reda O, et al:HTLV-1 infection promotes excessive T cell activation and transformation into adult T cell leukemia/lymphoma. J Clin Invest 131:e150472, 2021.
PubMed
P.17 掲載の参考文献
1) 日本小児血液・がん学会:疾患登録 2017年診断症例集計. [https://www.jspho.org/pdf/2017.pdf]
 
2) Murphy SB:Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas:dissimilarities from lymphomas in adults. Semin Oncol 7:332-339, 1980.
PubMed
3) Campo E, Jaffe ES, Cook JR, et al:The International Consensus Classification of Mature Lymphoid Neoplasms:a report from the Clinical Advisory Committee. Blood 140:1229-1253, 2022.
PubMed
4) 古賀友紀, 熊谷昌明, 瀧本哲也, ほか:本邦における小児Hodgkinリンパ腫157例の後方視的検討. -小児がん研究4グループによる調査-. 臨床血液 53:443-449, 2012.
 
5) 日本小児血液・がん学会(編):小児血液・腫瘍学 改訂第2版, p513, 診断と治療社, 2022.
 
6) Bonn BR, Rohde M, Zimmermann M, et al:Incidence and prognostic relevance of genetic variations in T-cell lymphoblastic lymphoma in childhood and adolescence. Blood 121:3153-3160, 2013.
 
7) Pinkel D, Johnson W, Aur RJ:Non-Hodgkin's lymphoma in children. Br J Cancer Suppl 2:298-323, 1975.
PubMed
8) Reiter A, Schrappe M, Ludwig WD, et al:Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma:a BFM group report. Blood 95:416-421, 2000.
 
9) Sunami S, Sekimizu M, Takimoto T, et al:Prognostic Impact of Intensified Maintenance Therapy on Children With Advanced Lymphoblastic Lymphoma:A Report From the Japanese Pediatric Leukemia/Lymphoma Study Group ALB-NHL03 Study. Pediatr Blood Cancer 63:451-457, 2016.
 
10) Tsurusawa M, Mori T, Kikuchi A, et al:Improved treatment results of children with B-cell non-Hodgkin lymphoma:a report from the Japanese Pediatric Leukemia/Lymphoma Study Group B-NHL03 study. Pediatr Blood Cancer 61:1215-1221, 2014.
 
11) Minard-Colin V, Auperin A, Pillon M, et al:Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children. N Engl J Med 382:2207-2219, 2020.
PubMed
12) Brugieres L, Le Deley MC, Rosolen A, et al:Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma:Results of a randomized trial of the EICNHL Group. J Clin Oncol 27:897-903, 2009.
 
13) Kobayashi R, Yamato K, Tanaka F, et al:Retrospective analysis of non-anaplastic peripheral T-cell lymphoma in pediatric patients in Japan. Pediatr Blood Cancer 54:212-215, 2010.
PubMed
14) Kobayashi R, Tanaka F, Nakazawa A, et al:Pediatric follicular lymphoma in Japan. Int J Hematol 105:849-853, 2017.
PubMed
P.20 掲載の参考文献
1) Ferlay J, Ervik M, Lam F, et al:Global Cancer Observatory:Cancer Today. International Agency for Research on Cancer, Lyon, 2020. [https://gco.iarc.fr/today].
 
2) Thandra KC, Barsouk A, Saginala K, et al:Epidemiology of Non-Hodgkin's Lymphoma. Med Sci(Basel) 9:5, 2021.
PubMed
3) Lavanchy D:Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 17:107-115, 2011.
PubMed
4) Negro F, Alberti A:The global health burden of hepatitis C virus infection. Liver Int 31(Suppl 2):1-3, 2011.
 
5) Kuniyoshi M, Nakamuta M, Sakai H, et al:Prevalence of hepatitis B or C virus infections in patients with non-Hodgkin's lymphoma. J Gastroenterol Hepatol 16:215-219, 2001.
PubMed
6) Negri E, Little D, Boiocchi M, et al:B-cell non-Hodgkin's lymphoma and hepatitis C virus infection:a systematic review. Int J Cancer 111:1-8, 2004.
PubMed
7) Matsuo K, Kusano A, Sugumar A, et al:Effect of hepatitis C virus infection on the risk of non-Hodgkin's lymphoma:a meta-analysis of epidemiological studies. Cancer Sci 95:745-752, 2004.
PubMed
8) Abe SK, Inoue M, Sawada N, et al:Hepatitis B and C virus infection and risk of lymphoid malignancies:A population-based cohort study(JPHC Study). Cancer Epidemiol 39:562-566, 2015.
 
P.26 掲載の参考文献
1) Swerdlow SH, Campo E, Harris NL, et al:Lymphomas associated with HIV infection. In:WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th ed(ed by Swerdlow SH, Campo E, Harris NL, et al), P:449-452, IARC, Lyon, 2017.
 
2) Morlat P, Roussillon C, Henard S, et al:Causes of death among HIV-infected patients in France in 2010(national survey):trends since 2000. AIDS 28:1181-1191, 2014.
PubMed
3) Nishijima T, Inaba Y, Kawasaki Y, et al:Mortality and causes of death in people living with HIV in the era of combination antiretroviral therapy compared with the general population in Japan. AIDS34:913-921, 2020.
PubMed
4) Katano H, Hishima T, Mochizuki M, et al:The prevalence of opportunistic infections and malignancies in autopsied patients with human immunodeficiency virus infection in Japan. BMC Infect Dis 14:229, 2014.
PubMed
5) Engels EA, Biggar RJ, Hall HI, et al:Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 123:187-194, 2008.
PubMed
6) Carbone A, Vaccher E, Gloghini A:Hematologic cancers in individuals infected by HIV. Blood 139:995-1012, 2022.
PubMed
7) Raphael M, Said J, Borisch B, et al:Lymphomas associated with HIV infection. In:WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues(ed by Swerdlow SH, Campo E, Harris NL, et al), p340-342, IARC, Lyon, 2008.
 
8) Rubinstein PG, Aboulafia DM, Zloza A:Malignancies in HIV/AIDS:from epidemiology to therapeutic challenges. AIDS 28:453-465, 2014.
PubMed
9) Ambinder RF:Epstein-Barr virus associated lymphoproliferations in the AIDS setting. Eur J Cancer 37:1209-1216, 2001.
PubMed
10) Miuma S, Hidaka M, Takatsuki M, et al:Current characteristics of hemophilia patients co-infected with HIV/HCV in Japan. Exp Ther Med 15:2148-2155, 2018.
PubMed
11) Schollkopf C, Smedby KE, Hjalgrim H, et al:Hepatitis C infection and risk of malignant lymphoma. Int J Cancer 122:1885-1890, 2008.
PubMed
12) Besson C, Noel N, Lancar R, et al:Hepatitis C virus or hepatitis B virus coinfection and lymphoma risk in people living with HIV. AIDS 34:599-608, 2020
PubMed
13) Housri N, Yarchoan R, Kaushal A:Radiotherapy for patients with the human immunodeficiencyvirus:are special precautions necessary? Cancer 116:273-283, 2010.
 
14) Nagai H, Odawara T, Ajisawa A, et al:Whole brain radiation alone produces favourable outcomes for AIDS-related primary central nervous system lymphoma in the HAART era. Eur J Haematol 84:499-505, 2010.
PubMed
15) Kelly GL, Rickinson AB:Burkitt lymphoma:revisiting the pathogenesis of a virus-associated malignancy. Hematology Am Soc Hematol Educ Program 2007:277-284, 2007.
PubMed
16) Kojima Y, Hagiwara S, Uehira T, et al:Clinical Outcomes of AIDS-related Burkitt Lymphoma:A Multi-institution Retrospective Survey in Japan. Jpn J Clin Oncol 44:318-323, 2014.
PubMed
17) Ota Y, Hishima T, Mochizuki M, et al:Classification of AIDS-related lymphoma cases between 1987 and 2012 in Japan based on the WHO classification of lymphomas, fourth edition. Cancer Med 3:143-153, 2014.
PubMed
18) Okada S, Goto H, Yotsumoto M:Current status of treatment for primary effusion lymphoma. Intractable Rare Dis Res 3:65-74, 2014.
PubMed
19) Hagiwara S, Nagai H, Tanaka J, et al:The current state of human immunodeficiency virus-associated lymphoma in Japan:a nationwide retrospective study of the Japanese Society of Hematology Blood Disease Registry. Int J Hematol 110:244-249, 2019.
PubMed
20) Castillo JJ, Bibas M, Miranda RN:The biology and treatment of plasmablastic lymphoma. Blood 125:2323-2330, 2015.
PubMed
21) Herida M, Mary-Krause M, Kaphan R, et al:Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol 21:3447-3453, 2003.
 
22) Re A, Casari S, Cattaneo C, et al:Hodgkin disease developing in patients infected by human immunodeficiency virus results in clinical features and a prognosis similar to those in patients with human immunodeficiency virus-related non-Hodgkin lymphoma. Cancer 92:2739-2745, 2001.
 
23) Yotsumoto M, Hagiwara S, Ajisawa A, et al:Clinical characteristics of human immunodeficiency virus-associated Hodgkin lymphoma patients in Japan. Int J Hematol 96:247-253, 2012.
PubMed
24) Mahale P, Ugoji C, Engels EA, et al:Cancer risk following lymphoid malignancies among HIV-infected people. AIDS 34:1237-1245, 2020.
PubMed
P.31 掲載の参考文献
1) Swerdlow SH, Campo E, Pileri SA, et al:The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127:2375-2390, 2016.
PubMed
2) Alaggio R, Amador C, Anagnostopoulos I, et al:The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours:Lymphoid Neoplasms. Leukemia 36:1720-1748, 2022.
PubMed
3) Miranda-Filho A, Pineros M, Znaor A, et al:Global patterns and trends in the incidence of non-Hodgkin lymphoma. Cancer Causes Control 30:489-499, 2019.
PubMed
4) Armitage JO, Gascoyne RD, Lunning MA, et al:Non-Hodgkin lymphoma. Lancet 390:298-310, 2017.
PubMed
5) 国立研究開発法人国立がん研究センター:がん情報サービス, 悪性リンパ腫. [https://ganjoho.jp/public/cancer/ML/index.html]
 
6) Siebert JD, Mulvaney DA, Vukov AM, et al:Utility of flow cytometry in subtyping composite and sequential lymphoma. J Clin Lab Anal 13:199-204, 1999.
PubMed
7) Acker B, Hoppe RT, Colby TV, et al:Histologic conversion in the non-Hodgkin's lymphomas. J Clin Oncol 1:11-16, 1983.
PubMed
8) Al-Mansour M, Connors JM, Gascoyne RD, et al:Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin's lymphoma. J Clin Oncol 28:793-799, 010.
 
9) Kim H:Composite lymphoma and related disorders. Am J Clin Pathol 99:445-451, 1993.
PubMed
10) Niino D, My Hanh LT, Miura S, et al:Incidence Patterns of Sequential or Composite Lymphoma:A Population-Based Cancer Registry Study. Tohoku J Exp Med 254:123-127, 2021.
PubMed
11) Fritz A, Percy C, Jack A, et al:International Classification of Diseases for Oncology(ICD-O), 3rd ed, World Health Organization, Geneva(Switzerland), 2001.
 
12) Tucci A, Motta M, Ungari M, et al:The development of more than one histologic type of lymphomain the same patient is frequent and confers a worse prognosis. Haematologica 90:348-352, 2005.
 
13) Khristi J, Mey U, Kirfel J, et al:Sequential Hodgkin's and non-Hodgkin's lymphoma in non-immunocompromised patients. Ann Hematol 92:1565-1567, 2013.
PubMed
14) Aussedat G, Traverse-Glehen A, Stamatoullas A, et al:Composite and sequential lymphoma between classical Hodgkin lymphoma and primary mediastinal lymphoma/diffuse large B-cell lymphoma, a clinico-pathological series of 25 cases. Br J Haematol 189:244-256, 2020.
 
P.35 掲載の参考文献
1) Khanmohammadi S, Shabani M, Tabary M, et al:Lymphoma in the setting of autoimmune diseases:A review of association and mechanisms. Crit Rev Oncol Hematol 150:102945, 2020.
PubMed
2) Ekstrom Smedby K, Vajdic CM, Falster M, et al:Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes:a pooled analysis within the InterLymph Consortium. Blood 111:4029-4038, 2008.
PubMed
3) Kaiser R:Incidence of lymphoma in patients with rheumatoid arthritis:a systematic review of the literature. Clin Lymphoma Myeloma 8:87-93, 2008.
PubMed
4) Baecklund E, Iliadou A, Askling J, et al:Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 54:692-701, 2006.
 
5) Lofstrom B, Backlin C, Sundstrom C, et al:A closer look at non-Hodgkin's lymphoma cases in a national Swedish systemic lupus erythematosus cohort:a nested case-control study. Ann Rheum Dis66:1627-1632, 2007.
 
6) Solans-Laque R, Lopez-Hernandez A, Bosch-Gil JA, et al:Risk, predictors, and clinical characteristics of lymphoma development in primary Sjogren's syndrome. Semin Arthritis Rheum 41:415-423, 2011.
PubMed
7) Goules AV, Argyropoulou OD, Pezoulas VC, et al:Primary Sjogren's Syndrome of Early and Late Onset:Distinct Clinical Phenotypes and Lymphoma Development. Front Immunol 11:594096, 2020.
PubMed
8) Cornec D, Devauchelle-Pensec V, Tobon GJ, et al:B cells in Sjogren's syndrome:from patho-physiology to diagnosis and treatment. J Autoimmun 39:161-167, 2012.
 
9) Hansen A, Reiter K, Pruss A, et al:Dissemination of a Sjogren's syndrome-associated extranodal marginal-zone B cell lymphoma:circulating lymphoma cells and invariant mutation pattern of nodal Ig heavy-and light-chain variable-region gene rearrangements. Arthritis Rheum 54:127-137, 2006.
PubMed
10) Baecklund E, Smedby KE, Sutton LA, et al:Lymphoma development in patients with autoimmune and inflammatory disorders--what are the driving forces? Semin Cancer Biol 24:61-70, 2014.
PubMed
11) Tsai HF, Hsu PN:Interplay between Helicobacter pylori and immune cells in immune pathogenesis of gastric inflammation and mucosal pathology. Cell Mol Immunol 7:255-259, 2010.
PubMed
12) Kuo SH, Yeh KH, Chen LT, et al:Helicobacter pylori-related diffuse large B-cell lymphoma of the stomach:a distinct entity with lower aggressiveness and higher chemosensitivity. Blood Cancer J 4:e220, 2014.
 
13) Bizjak M, Selmi C, Praprotnik S, et al:Silicone implants and lymphoma:The role of inflammation. J Autoimmun 65:64-73, 2015.
 
14) Alotaibi S, Hamadani M, Al-Mansour M, et al:Breast Implant-associated Anaplastic Large Cell Lymphoma. Clin Lymphoma Myeloma Leuk 21:e272-e276, 2021.
PubMed
15) U. S. Food and Drug Administration:Anaplastic Large Cell Lymphoma(ALCL) In Women with Breast Implants:Preliminary FDA Findings and Analysis. 2011.
 
16) Kim B, Predmore ZS, Mattke S, et al:Breast implant-associated anaplastic large cell lymphoma:updated results from a structured expert consultation process. Plast Reconstr Surg Glob Open 3:e296, 2015.
PubMed
P.39 掲載の参考文献
1) Kerzin-Storrar L, Faed MJ, MacGillivray JB, et al:Incidence of familial Hodgkin's disease. Br J Cancer 47:707-712, 1983.
PubMed
2) Alligon M, Mahlaoui N, Courteille V, et al:An appraisal of the frequency and severity of noninfectious manifestations in primary immunodeficiencies:A study of a national retrospective cohort of 1375 patients over 10 years. J Allergy Clin Immunol 149:2116-2125, 2022.
PubMed
3) Morio T:Common variable immunodeficiency:the spectrum of disease manifestations and molecular basis of the disorder. Rinsho Ketsueki 54:1983-1991, 2013.
PubMed
4) Egg D, Schwab C, Gabrysch A, et al:Increased Risk for Malignancies in 131 Affected CTLA4 Mutation Carriers. Front Immunol 9:2012, 2018.
PubMed
5) Bougeard G, Renaux-Petel M, Flaman JM, et al:Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers. J Clin Oncol 33:2345-2352, 2015.
PubMed
6) Ripperger T, Schlegelberger B:Acute lymphoblastic leukemia and lymphoma in the context of constitutional mismatch repair deficiency syndrome. Eur J Med Genet 59:133-142, 2016.
PubMed
7) Wang SS, Vajdic CM, Linet MS, et al:B-Cell NHL Subtype Risk Associated with Autoimmune Conditions and PRS. Cancer Epidemiol Biomarkers Prev 31:1103-1110, 2022.
PubMed
8) Cerhan JR, Slager SL:Familial predisposition and genetic risk factors for lymphoma. Blood 126:2265-2273, 2015.
PubMed
9) Skibola CF, Curry JD, Nieters A:Genetic susceptibility to lymphoma. Haematologica 92:960-969, 2007.
PubMed
10) Cerhan JR, Berndt SI, Vijai J, et al:Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. Nat Genet 46:1233-1238, 2014.
PubMed
11) Skibola CF, Berndt SI, Vijai J, et al:Genome-wide association study identifies five susceptibility loci for follicular lymphoma outside the HLA region. Am J Hum Genet 95:462-471, 2014.
PubMed
12) Vijai J, Wang Z, Berndt SI, et al:A genome-wide association study of marginal zone lymphoma shows association to the HLA region. Nat Commun 6:5751, 2015.
 
13) Cozen W, Timofeeva MN, Li D, et al:A meta-analysis of Hodgkin lymphoma reveals 19p13. 3 TCF3 as a novel susceptibility locus. Nat Commun 5:3856, 2014.
 
14) Sud A, Thomsen H, Orlando G, et al:Genome-wide association study implicates immune dysfunction in the development of Hodgkin lymphoma. Blood 132:2040-2052, 2018.
PubMed
15) Chen C, Song N, Dong Q, et al:Association of Single-Nucleotide Variants in the Human Leukocyte Antigen and Other Loci With Childhood Hodgkin Lymphoma. JAMA Netw Open 5:e2225647, 2022.
PubMed
P.45 掲載の参考文献
1) Swerdlow SH, Campo E, Harris NL, et al(ed):WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed. IARC Press, Lyon, 2017.
 
2) Takehana CS, Twist CJ, Mosci C, et al:(18)F-FDG PET/CT in the management of patients with post-transplant lymphoproliferative disorder. Nucl Med Commun 35:276-281, 2014.
PubMed
3) Natkunam Y, Gratzinger D, Chadburn A, et al:Immunodeficiency-associated lymphoproliferativedisorders:time for reappraisal? Blood 132:1871-1878, 2018.
 
4) Dierickx D, Habermann TM:Post-Transplantation Lymphoproliferative Disorders in Adults. N Engl J Med 378:549-562, 2018.
PubMed
5) Fujimoto A, Hiramoto N, Yamasaki S, et al:Risk Factors and Predictive Scoring System For Post-Transplant Lymphoproliferative Disorder after Hematopoietic Stem Cell Transplantation. Bio Blood Marrow Transplant 25:1441-1449, 2019.
 
6) Petrara MR, Giunco S, Serraino D, et al:Post-transplant lymphoproliferative disorders:from epidemiology to pathogenesis-driven treatment. Cancer Lett 369:37-44, 2015.
PubMed
7) van der Velden WJFM, Mori T, Stevens WBC, et al:Reduced PTLD-related mortality in patients experiencing EBV infection following allo-SCT after the introduction of a protocol incorporating pre-emptive rituximab. Bone Marrow Transplant 48:1465-1471, 2013.
PubMed
8) Dierickx D, Tousseyn T, Gheysens O:How I treat posttransplant lymphoproliferative disorders. Blood 126:2274-2283, 2015.
 
9) Choquet S, Leblond V, Herbrecht R, et al:Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders:results of a prospective multicenter phase 2 study. Blood 107:3053-3057, 2006.
 
10) Trappe RU, Dierickx D, Zimmermann H, et al:Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful stratification into rituximab or R-CHOP consolidation in an international, prospective, multicenter Phase II trial. J Clin Oncol 35:536-543, 2017.
 
11) Schiefer AI, Salzer E, Fureder A, et al:PD-L1 and PD1 expression in post-transplantation lymphoproliferative disease(PTLD) of childhood and adolescence:An inter-and intra-individual descriptive study covering the whole spectrum of PTLD categories. Cancer Med 8:4656-4668, 2019.
PubMed
12) Vase MO, Maksten EF, Bendix K, et al:Occurrence and prognostic relevance of CD30 expression in post-transplant lymphoproliferative disorders. Leuk Lymphoma 56:1677-1685, 2015.
PubMed
13) Evens AM, David KA, Helenowski I, et al:Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease:outcomes and prognostic factors in the modern era. J Clin Oncol 28:1038-1046, 2010.
PubMed
14) Ricciardelli I, Blundell MP, Brewin J, et al:Towards gene therapy for EBV-associated posttransplant lymphoma with genetically modified EBV-specific cytotoxic T cells. Blood 124:2514-2522, 2014.
PubMed
15) Luttwak E, Hagin D, Perry C, et al:Anti-CD19 CAR-T therapy for EBV-negative posttransplantation lymphoproliferative disease-a single center case series. Bone Marrow Transplant 56:1031-1037, 2021.
PubMed
P.50 掲載の参考文献
1) Swerdlow SH, Campo E, Harris NL, et al(ed):WHO Classification of Tumours of Haematopoietic and lymphoid Tissues, Revised 4th Edition, IARC Press, Lyon, 2017.
 
2) リウマトレックス適正使用情報 vol.27, 重篤な副作用及び死亡症例の発現状況. ファイザー株式会社, 2021.
 
3) 関節リウマチ関連リンパ増殖性疾患の診断と管理の手引き(3学会合同RA関連LPDワーキンググループ(日本リウマチ学会, 日本血液学会, 日本病理学会)編), 羊土社, 2022.
 
4) Kurita D, Miyoshi H, Ichikawa A, et al:Methotrexate-associated Lymphoproliferative Disorders in Patients With Rheumatoid Arthritis:Clinicopathologic Features and Prognostic Factors. Am J Surg Pathol 43:869-884, 2019.
PubMed
5) Zintzaras E, Voulgarelis M, Moutsopoulos HM:The risk of lymphoma development in autoimmune diseases:a meta-analysis. Arch Intern Med 165:2337-2344, 2005.
PubMed
6) Hashimoto A, Chiba N, Tsuno H, et al:Incidence of malignancy and the risk of lymphoma in Japanese patients with rheumatoid arthritis compared to the general population. J Rheumatol 42:564-571, 2015.
 
7) Kameda T, Dobashi H, Miyatake N, et al:Association of higher methotrexate dose with lymproliferative disease onset in rheumatoid arthritis patients. Arthritis Care Res(Hoboken) 66:1302-1309, 2014.
 
8) Harada T, Iwasaki H, Muta T, et al:Outcomes of methotrexate-associated lymphoproliferative disorders in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs. Br JHaematol 194:101-110, 2021.
PubMed
9) Hemminki K, Li X, Sundquist K, et al:Cancer risk in hospitalized rheumatoid arthritis patients. Rheumatology(Oxford) 47:698-701, 2008.
PubMed
10) Di M, Huntington SF, Olszewski AJ:Challenges and Opportunities in the Management of Diffuse Large B-Cell Lymphoma in Older Patients. Oncologist 26:120-132, 2021.
PubMed
11) Castillo JJ, Beltran BE, Miranda RN, et al:EBV-positive diffuse large B-cell lymphoma, not otherwise specified:2018 update on diagnosis, risk-stratification and management. Am J Hematol 93:953-962, 2018.
 
12) Wolfe F:Inflammatory activity, but not methotrexate or prednisone use predicts non-Hodgkin's lymphoma in rheumatoid arthritis:a 25-year study of 1, 767 RA patients. Arthritis Rheum 41(Suppl):931S, 1998.
 
13) Yamakawa N, Fujimoto M, Kawabata D, et al:A clinical, pathological, and genetic characterization of methotrexate-associated lymphoproliferative disorders. J Rheumatol 41:293-299, 2014.
PubMed
14) Takada H, Kaneko Y, Nakano K, et al:Clinicopathological characteristics of lymphoproliferative disorders in 232 patients with rheumatoid arthritis in Japan:A retrospective, multicenter, descriptive study. Mod Rheumatol 32:32-40, 2022.
PubMed
15) Kuramoto N, Saito S, Fujii T, et al:Characteristics of rheumatoid arthritis with immunodeficiency-associated lymphoproliferative disorders to regress spontaneously by the withdrawal of methotrexate and their clinical course:A retrospective, multicenter, case-control study. Mod Rheumatol 32:24-31, 2022.
PubMed

[II] 悪性リンパ腫の分子腫瘍学的異常・病態形成機序

P.57 掲載の参考文献
1) Marti GE, Rawstron AC, Ghia P, et al:Diagnostic criteria for monoclonal B-cell lymphocytosis. Br J Haematol 130:325-332, 2005.
PubMed
2) Landgren O, Albitar M, Ma W, et al:B-cell clones as early markers for chronic lymphocytic leukemia. N Engl J Med 360:659-667, 2009.
 
3) Lanasa MC, Allgood SD, Volkheimer AD, et al:Single-cell analysis reveals oligoclonality among 'low-count' monoclonal B-cell lymphocytosis. Leukemia 24:133-140, 2010.
PubMed
4) Sanchez ML, Almeida J, Gonzalez D, et al:Incidence and clinicobiologic characteristics of leukemic B-cell chronic lymphoproliferative disorders with more than one B-cell clone. Blood 102:2994-3002, 2003.
 
5) Kikushige Y, Ishikawa F, Miyamoto T, et al:Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia. Cancer Cell 20:246-259, 2011.
PubMed
6) Damm F, Mylonas E, Cosson A, et al:Acquired initiating mutations in early hematopoietic cells of CLL patients. Cancer Discov 4:1088-1101, 2014.
PubMed
7) Quijada-Alamo M, Hernandez-Sanchez M, Robledo C, et al:Next-generation sequencing and FISH studies reveal the appearance of gene mutations and chromosomal abnormalities in hematopoietic progenitors in chronic lymphocytic leukemia. J Hematol Oncol 10:83, 2017.
PubMed
8) Zenz T, Mertens D, Kuppers R, et al:From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 10:37-50, 2010.
PubMed
9) Fabbri G, Dalla-Favera R:The molecular pathogenesis of chronic lymphocytic leukaemia. Nat Rev Cancer 16:145-162, 2016.
PubMed
10) Landau DA, Tausch E, Taylor-Weiner AN, et al:Mutations driving CLL and their evolution in progression and relapse. Nature 526:525-530, 2015.
PubMed
11) Burger JA, Chiorazzi N:B cell receptor signaling in chronic lymphocytic leukemia. Trends Immunol 34:592-601, 2013.
PubMed
12) Hoogeboom R, van Kessel KP, Hochstenbach F, et al:A mutated B cell chronic lymphocytic leukemia subset that recognizes and responds to fungi. J Exp Med 210:59-70, 2013.
PubMed
13) Kostareli E, Gounari M, Janus A, et al:Antigen receptor stereotypy across B-cell lymphoprolifera-tions:the case of IGHV4-59/IGKV3-20 receptors with rheumatoid factor activity. Leukemia 26:1127-1131, 2012.
 
14) Hoogeboom R, Wormhoudt TA, Schipperus MR, et al:A novel chronic lymphocytic leukemia subset expressing mutated IGHV3-7-encoded rheumatoid factor B-cell receptors that are functionally proficient. Leukemia 27:738-740, 2013.
PubMed
15) Herve M, Xu K, Ng YS, et al:Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing different antibody reactivity. J Clin Invest 115:1636-1643, 2005.
PubMed
16) Chu CC, Catera R, Hatzi K, et al:Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA. Blood 112:5122-5129, 2008.
PubMed
17) Lanemo Myhrinder A, Hellqvist E, Sidorova E, et al:A new perspective:molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies. Blood 111:3838-3848, 2008.
 
18) Duhren-von Minden M, Ubelhart R, Schneider D, et al:Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature 489:309-312, 2012.
PubMed
19) Tsujimoto Y, Cossman J, Jaffe E, et al:Involvement of the bcl-2 gene in human follicular lymphoma. Science 228:1440-1443, 1985.
PubMed
20) McDonnell TJ, Deane N, Platt FM, et al:bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 57:79-88, 1989.
PubMed
21) Cimmino A, Calin GA, Fabbri M, et al:miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 102:13944-13949, 2005.
PubMed
22) Klein U, Lia M, Crespo M, et al:The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell 17:28-40, 2010.
PubMed
P.62 掲載の参考文献
1) Alaggio R, et al:The 5th edition of the World Health Organization Classification of Hematolymphoid Tumors:Lymphoid Neoplasms. Leukemia 36:1720-1748, 2022.
 
2) Campo E, et al:The International Consensus classification of Mature Lymphoid Neoplasms:a report from the Clinical Advisory Committee. Blood 140:1229-1253, 2022.
PubMed
3) Treon SP, Xu L, Yang G, et al:MYD88 L265P somatic mutation in Waldenstrom's macroglobuline-mia. N Engl J Med 367:826-833, 2012.
 
4) Bonnert TP, Garka KE, Parnet P, et al:The cloning and characterization of human MyD88:a member of an IL-1 receptor related family. FEBS Lett 402:81-84, 1997.
 
5) Ngo VN, Young RM, Schmitz R, et al:Oncogenically active MYD88 mutations in human lymphoma. Nature 470:115-119, 2011.
PubMed
6) Watters TM, Kenny EF, O'Neill LA:Structure, function and regulation of the Toll/IL-1 receptor adaptor proteins. Immunol Cell Biol 85:411-419, 2007.
PubMed
7) Lam LT, Wright G, Davis RE, et al:Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-κB pathways in subtypes of diffuse large B-cell lymphoma. Blood 111:3701-3713, 2008.
 
8) Poulain S, Roumier C, Venet-Caillault A, et al:Genomic Landscape of CXCR4 Mutations in Waldenstrom Macroglobulinemia. Clin Cancer Res 22:1480-1488, 2016.
PubMed
9) Treon SP, Tripsas CK, Meid K, et al:Ibrutinib in previously treated Waldenstroms macroglobuline-mia N Engl J Med 372:1430-1440, 2015.
 
10) Poulain S, Roumier C, Bertrand E, et al:TP53 Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia. Clin Cancer Res 23:6325-6335, 2017.
PubMed
11) Sekiguchi N, Nomoto J, Nagata A, et al:Gene expression profile signature of aggressive Waldenstrom macroglobulinemia with chromosome 6q deletion. Biomed Res Int 2018:6728128, 2018.
PubMed
12) Dimopoulos MA, Kastritis E, Owen RG, et al:Treatment recommendations for patients with Waldenstrom macroglobulinemia(WM) and related disorders:IWWM-7 consensus. Blood 124:1404-1411, 2014.
PubMed
13) Owen RG, Kyle RA, Stone MJ, et al:Response assesment in Waldenstrom macroglobulinemia:update from the VIth International Workshop. Br J Haematol 160:171-176, 2013.
 
14) Kastritis E, Morel P, Duhamel A, et al:A revised international prognostic score system for Waldenstrom's macroglobulinemia. Leukemia 33:2654-2661, 2019.
PubMed
P.69 掲載の参考文献
1) Nadeu F, Martin-Garcia D, Clot G, et al:Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes. Blood 136:1419-1432, 2020.
PubMed
2) Chen RW, Bemis LT, Amato CM, et al:Truncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphoma. Blood 112:822-829, 2008.
PubMed
3) Chinen Y, Tsukamoto T, Maegawa-Matsui S, et al:Tumor-specific transcript variants of cyclin D1 in mantle cell lymphoma and multiple myeloma with chromosome 11q13 abnormalities. Exp Hematol 84:45-53. e1, 2020.
 
4) Palomero J, Vegliante MC, Rodriguez ML, et al:SOX11 promotes tumor angiogenesis through transcriptional regulation of PDGFA in mantle cell lymphoma. Blood 124:2235-2247, 2014.
PubMed
5) Vegliante MC, Palomero J, Perez-Galan P, et al:SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma. Blood 121:2175-2185, 2013.
PubMed
6) Balsas P, Palomero J, Eguileor A, et al:SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma. Blood 130:501-513, 2017.
PubMed
7) Kuo PY, Jatiani SS, Rahman AH, et al:SOX11 augments BCR signaling to drive MCL-like tumor development. Blood 131:2247-2255, 2018.
PubMed
8) Vilarrasa-Blasi R, Verdaguer-Dot N, Belver L, et al:Insights into the mechanisms underlying aberrant SOX11 oncogene expression in mantle cell lymphoma. Leukemia 36:583-587, 2022.
PubMed
9) Mohanty A, Sandoval N, Phan A, et al:Regulation of SOX11 expression through CCND1 and STAT3 in mantle cell lymphoma. Blood 133:306-318, 2019.
PubMed
10) Matsumura-Kimoto Y, Tsukamoto T, Shimura Y, et al:Serine-227 in the N-terminal kinase domain of RSK2 is a potential therapeutic target for mantle cell lymphoma. Cancer Med 9:5185-5199, 2020.
 
11) Thurner L, Fadle N, Bittenbring JT, et al:LRPAP1 autoantibodies in mantle cell lymphoma are associated with superior outcome. Blood 137:3251-3258, 2021.
PubMed
12) Queiros AC, Beekman R, Vilarrasa-Blasi R, et al:Decoding the DNA Methylome of Mantle Cell Lymphoma in the Light of the Entire B Cell Lineage. Cancer Cell 30:806-821, 2016.
PubMed
13) Agarwal R, Chan YC, Tam CS, et al:Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma. Nat Med 25:119-129, 2019.
PubMed
14) Chiron D, Bellanger C, Papin A, et al:Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma. Blood 128:2808-2818, 2016.
PubMed
15) Balsas P, Veloza L, Clot G, et al:SOX11, CD70, and Treg cells configure the tumor-immune microenvironment of aggressive mantle cell lymphoma. Blood 138:2202-2215, 2021.
PubMed
P.74 掲載の参考文献
1) Carbone A, Roulland S, Gloghini A, et al:Follicular lymphoma. Nat Rev Dis Primers 5:83, 2019.
PubMed
2) Beguelin W, Teater M, Meydan C, et al:Mutant EZH2 Induces a Pre-malignant Lymphoma Niche by Reprogramming the Immune Response. Cancer Cell 37:655-673. e11, 2020.
 
3) Ennishi D, Takata K, Beguelin W, et al:Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition. Cancer Discov 9:546-563, 2019.
PubMed
4) Otsuka Y, Nishikori M, Arima H, et al:EZH2 inhibitors restore epigenetically silenced CD58 expression in B-cell lymphomas. Mol Immunol 119:35-45, 2020.
 
5) Solal-Celigny P, Lepage E, Brousse N, et al:Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas:final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial. J Clin Oncol 16:2332-2338, 1998.
 
6) Marcus R, Davies A, Ando K, et al:Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. N Engl J Med 377:1331-1344, 2017.
PubMed
7) Leonard JP, Trneny M, Izutsu K, et al:AUGMENT:A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma. J ClinOncol 37:1188-1199, 2019.
PubMed
8) Morschhauser F, Tilly H, Chaidos A, et al:Tazemetostat for patients with relapsed or refractory follicular lymphoma:an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol 21:1433-1442, 2020.
PubMed
9) Alonso-Alvarez S, Manni M, Montoto S, et al:Primary refractory follicular lymphoma:a poor outcome entity with high risk of transformation to aggressive B cell lymphoma. Eur J Cancer 157:132-139, 2021.
PubMed
10) Link BK, Maurer MJ, Nowakowski GS, et al:Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era:a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource. J Clin Oncol 31:3272-3278, 2013.
 
11) Kridel R, Chan FC, Mottok A, et al:Histological Transformation and Progression in Follicular Lymphoma:A Clonal Evolution Study. PLoS Med 13:e1002197, 2016.
PubMed
12) Freeman CL, Kridel R, Moccia AA, et al:Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma. Blood 134:761-764, 2019.
PubMed
13) Mozas P, Nadeu F, Rivas-Delgado A, et al:Patterns of change in treatment, response, and outcome in patients with follicular lymphoma over the last four decades:a single-center experience. Blood Cancer J 10:31, 2020.
PubMed
14) Bolen CR, Mattiello F, Herold M, et al:Treatment dependence of prognostic gene expression signatures in de novo follicular lymphoma. Blood 137:2704-2707, 2021.
PubMed
15) Haebe S, Shree T, Sathe A, et al:Single-cell analysis can define distinct evolution of tumor sites in follicular lymphoma. Blood 137:2869-2880, 2021.
PubMed
P.80 掲載の参考文献
1) Swerdlow SH, Campo E, Pileri SA, et al:The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127:2375-2390, 2016.
PubMed
2) Alizadeh AA, Eisen MB, Davis RE, et al:Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503-511, 2000.
PubMed
3) Rosenwald A, Wright G, Chan WC, et al:The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346:1937-1947, 2002.
PubMed
4) Lenz G, Wright G, Dave SS, et al:Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 359:2313-2323, 2008.
 
5) Scott DW, Wright GW, Williams PM, et al:Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood 123:1214-1217, 2014.
PubMed
6) Scott DW, Mottok A, Ennishi D, et al:Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies. J Clin Oncol 33:2848-2856, 2015.
PubMed
7) Ennishi D, Jiang A, Boyle M, et al:Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. J Clin Oncol 37:190-201, 2019.
PubMed
8) Sha C, Barrans S, Cucco F, et al:Molecular High-Grade B-Cell Lymphoma:Defining a Poor-Risk Group That Requires Different Approaches to Therapy. J Clin Oncol 37:202-212, 2019.
PubMed
9) Scott DW, King RL, Staiger AM, et al:High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology. Blood 131:2060-2064, 2018.
PubMed
10) Ennishi D, Mottok A, Ben-Neriah S, et al:Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin-specific clinical impact. Blood 129:2760-2770, 2017.
PubMed
11) Chong LC, Ben-Neriah S, Slack GW, et al:High-resolution architecture and partner genes of MYC rearrangements in lymphoma with DLBCL morphology. Blood Adv 2:2755-2765, 2018.
PubMed
12) Jamal-Hanjani M, Wilson GA, McGranahan N, et al:Tracking the Evolution of Non-Small-Cell Lung Cancer. N Engl J Med 376:2109-2121, 2017.
PubMed
13) Pasqualucci L, Trifonov V, Fabbri G, et al:Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet 43:830-837, 2011.
PubMed
14) Morin RD, Mendez-Lago M, Mungall AJ, et al:Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476:298-303, 2011.
PubMed
15) Lohr JG, Stojanov P, Lawrence MS, et al:Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma(DLBCL) by whole-exome sequencing. Proc Natl Acad Sci USA 109:3879-3884, 2012.
PubMed
16) Roschewski M, Staudt LM, Wilson WH:Diffuse large B-cell lymphoma-treatment approaches in the molecular era. Nat Rev Clin Oncol 11:12-23, 2014.
PubMed
17) Basso K, Dalla-Favera R:Germinal centres and B cell lymphomagenesis. Nat Rev Immunol 15:172-184, 2015.
 
18) Boice M, Salloum D, Mourcin F, et al:Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells. Cell 167:405-418. e13, 2016.
 
19) Muppidi JR, Schmitz R, Green JA, et al:Loss of signalling via Gα13 in germinal centre B-cell-derived lymphoma. Nature 516:254-258, 2014.
 
20) Pfeifer M, Grau M, Lenze D, et al:PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma. Proc Natl Acad Sci USA 110:12420-12425, 2013.
PubMed
21) Teater M, Dominguez PM, Redmond D, et al:AICDA drives epigenetic heterogeneity and accelerates germinal center-derived lymphomagenesis. Nat Commun 9:222, 2018.
PubMed
22) Ennishi D, Mottok A, Ben-Neriah S, et al:Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin-specific clinical impact. Blood 129:2760-2770, 2017.
PubMed
23) Chapuy B, Stewart C, Dunford AJ, et al:Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med 24:679-690, 2018.
PubMed
24) Schmitz R, Wright GW, Huang DW, et al:Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. N Engl J Med 378:1396-1407, 2018.
PubMed
25) Wright GW, Huang DW, Phelan JD, et al:A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. Cancer Cell 37:551-568. e14, 2020.
 
26) Lacy SE, Barrans SL, Beer PA, et al:Targeted sequencing in DLBCL, molecular subtypes, and outcomes:a Haematological Malignancy Research Network report. Blood 135:1759-1771, 2020.
 
27) Ennishi D, Hsi ED, Steidl C, et al:Toward a New Molecular Taxonomy of Diffuse Large B-cell Lymphoma. Cancer Discov 10:1267-1281, 2020.
 
28) Ennishi D, Takata K, Beguelin W, et al:Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition. Cancer Discov 9:546-563, 2019.
PubMed
29) Ennishi D, Healy S, Bashashati A, et al:TMEM30A loss-of-function mutations drive lymphomagene-sis and confer therapeutically exploitable vulnerability in B-cell lymphoma. Nat Med 26:577-588, 2020.
 
P.86 掲載の参考文献
1) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed(ed by Swerdllow S, Campo E, Harris NL, et al), IARC, Lyon, 2017.
 
2) Chiba S, Sakata-Yanagimoto M:Advances in understanding of angioimmunoblastic T-cell lymphoma. Leukemia 34:2592-2606, 2020.
PubMed
3) Sakata-Yanagimoto M, Enami T, Yoshida K, et al:Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet 46:171-175, 2014.
PubMed
4) Fujisawa M, Sakata-Yanagimoto M, Nishizawa S, et al:Activation of RHOA-VAV1 signaling in angioimmunoblastic T-cell lymphoma. Leukemia 32:694-702, 2018.
PubMed
5) Sakata-Yanagimoto M:Multistep tumorigenesis in peripheral T cell lymphoma. Int J Hematol 102:523-527, 2015.
PubMed
6) Nguyen TB, Sakata-Yanagimoto M, Asabe Y, et al:Identification of cell-type-specific mutations in nodal T-cell lymphomas. Blood Cancer J 7:e516, 2017.
PubMed
7) Dobson R, Du PY, Raso-Barnett L, et al:Early detection of T-cell lymphoma with T follicular helper phenotype by RHOA mutation analysis. Haematologica 107:489-499, 2022.
 
8) Nagao R, Kikuti YY, Carreras J, et al:Clinicopathologic Analysis of Angioimmunoblastic T-cell Lymphoma With or Without RHOA G17V Mutation Using Formalin-fixed Paraffin-embeddedSections. Am J Surg Pathol 40:1041-1050, 2016.
PubMed
9) Ondrejka SL, Grzywacz B, Bodo J, et al:Angioimmunoblastic T-cell Lymphomas With the RHOA p.Gly17Val Mutation Have Classic Clinical and Pathologic Features. Am J Surg Pathol 40:335-341, 2016.
PubMed
10) Nguyen PN, Tran NTB, Nguyen TPX, et al:Clinicopathological Implications of RHOA Mutations in Angioimmunoblastic T-Cell Lymphoma:A Meta-analysis:RHOA mutations in AITL. ClinLymphoma Myeloma Leuk 21:431-438, 2021.
PubMed
11) Steinhilber J, Mederake M, Bonzheim I, et al:The pathological features of angioimmunoblastic T-cell lymphomas with IDH2R172 mutations. Mod Pathol 32:1123-1134, 2019.
PubMed
12) Muto H, Sakata-Yanagimoto M, Nagae G, et al:Reduced TET2 function leads to T-cell lymphoma with follicular helper T-cell-like features in mice. Blood Cancer J 4:e264, 2014.
 
13) Nishizawa S, Sakata-Yanagimoto M, Hattori K, et al:BCL6 locus is hypermethylated in angioimmunoblastic T-cell lymphoma. Int J Hematol 105:465-469, 2017.
PubMed
14) Nguyen TB, Sakata-Yanagimoto M, Fujisawa M, et al:Dasatinib Is an Effective Treatment for Angioimmunoblastic T-cell Lymphoma. Cancer Res 80:1875-1884, 2020.
PubMed
15) Fujisawa M, Nguyen TB, Abe Y, et al:Clonal germinal center B cells function as a niche for T-cell lymphoma. Blood 140:1937-1950, 2022.
 
P.94 掲載の参考文献
1) Alaggio R, Amador C, Anagnostopoulos I, et al:The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours:Lymphoid Neoplasms. Leukemia 36:1720-1748, 2022.
PubMed
2) Chihara D, Ito H, Matsuda T, et al:Differences in incidence and trends of haematological malignancies in Japan and the United States. Br J Haematol 164:536-545, 2014.
PubMed
3) Ng SY, Yoshida N, Christie AL, et al:Targetable vulnerabilities in T-and NK-cell lymphomas identified through preclinical models. Nat Commun 9:2024, 2018.
 
4) Parrilla Castellar ER, Jaffe ES, Said JW, et al:ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood 124:1473-1480, 2014.
PubMed
5) Iqbal J, Wright G, Wang C, et al:Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood 123:2915-2923, 2014.
PubMed
6) Amador C, Greiner TC, Heavican TB, et al:Reproducing the molecular subclassification of peripheral T-cell lymphoma-NOS by immunohistochemistry. Blood 134:2159-2170, 2019.
PubMed
7) Heavican TB, Bouska A, Yu J, et al:Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma. Blood 133:1664-1676, 2019.
PubMed
8) Herek TA, Bouska A, Lone W, et al:DNMT3A mutations define a unique biological and prognostic subgroup associated with cytotoxic T cells in PTCL-NOS. Blood 140:1278-1290, 2022.
PubMed
9) Wai CMM, Chen S, Phyu T, et al:Immune pathway upregulation and lower genomic instability distinguish EBV-positive nodal T/NK-cell lymphoma from ENKTL and PTCL-NOS. Haematologica 107:1864-1879, 2022.
PubMed
10) Sakata-Yanagimoto M, Fukumoto K, Karube K, et al:Molecular understanding of peripheral T-cell lymphomas, not otherwise specified(PTCL, NOS):A complex disease category. J Clin Exp Hematop 61:61-70, 2021.
PubMed
11) Ghione P, Faruque P, Mehta-Shah N, et al:T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma. Blood Adv 4:4640-4647, 2020.
PubMed
12) Watatani Y, Sato Y, Miyoshi H, et al:Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling. Leukemia 33:2867-2883, 2019.
 
13) Sugio T, Miyawaki K, Kato K, et al:Microenvironmental immune cell signatures dictate clinical outcomes for PTCL-NOS. Blood Adv 2:2242-2252, 2018.
PubMed
14) Yoshida N, Nishikori M, Izumi T, et al:Primary peripheral T-cell lymphoma, not otherwise specified of the thyroid with autoimmune thyroiditis. Br J Haematol 161:214-223, 2013.
 
P.101 掲載の参考文献
1) Matsuoka M, Jeang KT:Human T-cell leukaemia virus type 1(HTLV-1) infectivity and cellular transformation. Nat Rev Cancer 7:270-280, 2007.
PubMed
2) Cook LB, Fuji S, Hermine O, et al:Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report. J Clin Oncol 37:677-687, 2019.
PubMed
3) Ishitsuka K, Tamura K:Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma. Lancet Oncol 15:e517-e526, 2014.
PubMed
4) Kataoka K, Nagata Y, Kitanaka A, et al:Integrated molecular analysis of adult T cell leukemia/lymphoma. Nat Genet 47:1304-1315, 2015.
PubMed
5) Kogure Y, Kameda T, Koya J, et al:Whole-genome landscape of adult T-cell leukemia/lymphoma. Blood 139:967-982, 2022.
PubMed
6) Fujikawa D, Nakagawa S, Hori M, et al:Polycomb-dependent epigenetic landscape in adult T-cell leukemia. Blood 127:1790-1802, 2016.
PubMed
7) Kataoka K, Shiraishi Y, Takeda Y, et al:Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers. Nature 534:402-406, 2016.
PubMed
8) Rowan AG, Dillon R, Witkover A, et al:Evolution of retrovirus-infected premalignant T-cell clones prior to adult T-cell leukemia/lymphoma diagnosis. Blood 135:2023-2032, 2020.
PubMed
9) Stoeckius M, Hafemeister C, Stephenson W, et al:Simultaneous epitope and transcriptome measurement in single cells. Nat Methods 14:865-868, 2017.
PubMed
10) Koya J, Saito Y, Kameda T, et al:Single-Cell Analysis of the Multicellular Ecosystem in Viral Carcinogenesis by HTLV-1. Blood Cancer Discov 2:450-467, 2021.
PubMed
11) Kobayashi S, Nakano K, Watanabe E, et al:CADM1 expression and stepwise downregulation of CD7 are closely associated with clonal expansion of HTLV-I-infected cells in adult T-cell leukemia/lymphoma. Clin Cancer Res 20:2851-2861, 2014.
PubMed
12) Satou Y, Utsunomiya A, Tanabe J, et al:HTLV-1 modulates the frequency and phenotype of FoxP3+ CD4+ T cells in virus-infected individuals. Retrovirology 9:46, 2012.
PubMed
13) Kawashima M, Carreras J, Higuchi H, et al:PD-L1/L2 protein levels rapidly increase on monocytes via trogocytosis from tumor cells in classical Hodgkin lymphoma. Leukemia 34:2405-2417, 2020.
PubMed
14) Yamagishi M, Kubokawa M, Kuze Y, et al:Chronological genome and single-cell transcriptome integration characterizes the evolutionary process of adult T cell leukemia-lymphoma. Nat Commun 12:4821, 2021.
PubMed
15) Tan BJ, Sugata K, Reda O, et al:HTLV-1 infection promotes excessive T cell activation and transformation into adult T cell leukemia/lymphoma. J Clin Invest 131:e150472, 2021.
PubMed
P.106 掲載の参考文献
1) Swerdlow SH, Campo E, Harris NL, et al:WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues(Revised 4th edition), IARC, Lyon, 2017.
 
2) Brice P, de Kerviler E, Friedberg JW:Classical Hodgkin lymphoma. Lancet 398:1518-1527, 2021.
PubMed
3) Kuppers R, Engert A, Hansmann ML:Hodgkin lymphoma. J Clin Invest 122:3439-3447, 2012.
PubMed
4) Kapatai G, Murray P:Contribution of the Epstein Barr virus to the molecular pathogenesis of Hodgkin lymphoma. J Clin Pathol 60:1342-1349, 2007.
 
5) Weniger MA, Kuppers R:NF-κB deregulation in Hodgkin lymphoma. Semin Cancer Biol 39:32-39, 2016.
 
6) Joos S, Kupper M, Ohl S, et al:Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells. Cancer Res 60:549-552, 2000.
PubMed
7) Green MR, Monti S, Rodig SJ, et al:Integrative analysis reveals selective 9p24. 1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 116:3268-3277, 2010.
 
8) Roemer MGM, Redd RA, Cader FZ, et al:Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. J Clin Oncol 36:942-950, 2018.
PubMed
9) Carey CD, Gusenleitner D, Lipschitz M, et al:Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma. Blood 130:2420-2430, 2017.
PubMed
10) Reinke S, Brockelmann PJ, Iaccarino I, et al:Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1. Blood 136:2851-2863, 2020.
 
11) Cader FZ, Hu X, Goh WL, et al:A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma. Nat Med 26:1468-1479, 2020.
 
12) Nagasaki J, Togashi Y, Sugawara T, et al:The critical role of CD4+ T cells in PD-1 blockade against MHC-II-expressing tumors such as classic Hodgkin lymphoma. Blood Adv 4:4069-4082, 2020.
PubMed
13) Kawashima M, Carreras J, Higuchi H, et al:PD-L1/L2 protein levels rapidly increase on monocytes via trogocytosis from tumor cells in classical Hodgkin lymphoma. Leukemia 34:2405-2417, 2020.
PubMed
14) Ho WT, Pang WL, Chong SM, et al:Expression of CD137 on Hodgkin and Reed-Sternberg cells inhibits T-cell activation by eliminating CD137 ligand expression. Cancer Res 73:652-661, 2013.
PubMed
P.111 掲載の参考文献
1) Epstein MA, Barr YM:Cultivation in vitro of human lymphoblasts from Burkitt's malignant lymphoma. Lancet 1:252-253, 1964.
 
2) Henle G, Henle W, Diehl V:Relation of Burkitt's tumor-associated herpes-ytpe virus to infectious mononucleosis. Proc Natl Acad Sci USA 59:94-101, 1968.
PubMed
3) Alaggio R, Amador C, Anagnostopoulos I, et al:The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours:Lymphoid Neoplasms. Leukemia 36:1720-1748, 2022.
PubMed
4) Montes-Mojarro IA, Fend F, Quintanilla-Martinez L:EBV and the Pathogenesis of NK/T Cell Lymphoma. Cancers(Basel) 13:1414, 2021.
 
5) Okuno Y, Murata T, Sato Y, et al:Defective Epstein-Barr virus in chronic active infection and haematological malignancy. Nat Microbiol 4:404-413, 2019.
PubMed
6) Peng RJ, Han BW, Cai QQ, et al:Genomic and transcriptomic landscapes of Epstein-Barr virus in extranodal natural killer T-cell lymphoma. Leukemia 33:1451-1462, 2019.
PubMed
7) Iizasa H, Wulff BE, Alla NR, et al:Editing of Epstein-Barr virus-encoded BART6 microRNAs controls their dicer targeting and consequently affects viral latency. J Biol Chem 285:33358-33370, 2010.
PubMed
8) Fischer E, Delibrias C, Kazatchkine MD:Expression of CR2(the C3dg/EBV receptor, CD21) on normal human peripheral blood T lymphocytes. J Immunol 146:865-869, 1991.
 
9) Arai A:Chronic Active Epstein-Barr Virus Infection:The Elucidation of the Pathophysiology and the Development of Therapeutic Methods. Microorganisms 9:180, 2021.
PubMed
10) Anagnostopoulos I, Hummel M, Kreschel C, et al:Morphology, immunophenotype, and distribution of latently and/or productively Epstein-Barr virus-infected cells in acute infectious mononucleosis:implications for the interindividual infection route of Epstein-Barr virus. Blood 85:744-750, 1995.
PubMed
11) Nomura K, Kanegane H, Otsubo K, et al:Autoimmune lymphoproliferative syndrome mimicking chronic active Epstein-Barr virus infection. Int J Hematol 93:760-764, 2011.
PubMed
12) Bi XW, Wang H, Zhang WW, et al:PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma. J Hematol Oncol 9:109, 2016.
 
13) Kataoka K, Miyoshi H, Sakata S, et al:Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas. Leukemia 33:1687-1699, 2019.
PubMed
14) Yoshimori M, Shibayama H, Imadome KI, et al:Antineoplastic and anti-inflammatory effects of bortezomib on systemic chronic active EBV infection. Blood Adv 5:1805-1815, 2021.
PubMed
15) Nakamura M, Iwata S, Kimura H, et al:Elevated expression of activation-induced cytidine deaminase in T and NK cells from patients with chronic active Epstein-Barr virus infection. Eur J Dermatol 21:780-782, 2011.
 
P.117 掲載の参考文献
1) Aoki T, Chong LC, Takata K, et al:Single-Cell Transcriptome Analysis Reveals Disease-Defining T-cell Subsets in the Tumor Microenvironment of Classic Hodgkin Lymphoma. Cancer Discov 10:406-421, 2020.
PubMed
2) Alaggio R, Amador C, Anagnostopoulos I, et al:The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours:Lymphoid Neoplasms. Leukemia 36:1720-1748, 2022.
PubMed
3) de Charette M, Houot R:Hide or defend, the two strategies of lymphoma immune evasion:potential implications for immunotherapy. Haematologica 103:1256-1268, 2018.
PubMed
4) Lamaison C, Tarte K:B cell/stromal cell crosstalk in health, disease, and treatment:Follicular lymphoma as a paradigm. Immunol Rev 302:273-285, 2021.
PubMed
5) Kumar E, Pickard L, Okosun J:Pathogenesis of follicular lymphoma:genetics to the microenviron-ment to clinical translation. Br J Haematol 194:810-821, 2021.
 
6) Scott DW, Gascoyne RD:The tumour microenvironment in B cell lymphomas. Nat Rev Cancer 14:517-534, 2014.
 
7) Miyawaki K, Sugio T:Lymphoma Microenvironment in DLBCL and PTCL-NOS:the key to uncovering heterogeneity and the potential for stratification. J Clin Exp Hematop 62:127-135, 2022.
PubMed
8) Kotlov N, Bagaev A, Revuelta MV, et al:Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures. Cancer Discov 11:1468-1489, 2021.
PubMed
9) Miyawaki K, Kato K, Sugio T, et al:A germinal center-associated microenvironmental signature reflects malignant phenotype and outcome of DLBCL. Blood Adv 6:2388-2402, 2022.
PubMed
10) Ennishi D, Takata K, Beguelin W, et al:Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition. Cancer Discov 9:546-563, 2019.
PubMed
11) Kiyasu J, Miyoshi H, Hirata A, et al:Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. Blood 126:2193-2201, 2015.
PubMed
12) McCord R, Bolen CR, Koeppen H, et al:PD-L1 and tumor-associated macrophages in de novo DLBCL. Blood Adv 3:531-540, 2019.
PubMed
13) Griffin GK, Weirather JL, Roemer MGM, et al:Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma. Blood 137:1353-1364, 2021.
 
14) Sugio T, Miyawaki K, Kato K, et al:Microenvironmental immune cell signatures dictate clinical outcomes for PTCL-NOS. Blood Adv 2:2242-2252, 2018.
PubMed
15) Fujisawa M, Nguyen TB, Abe Y, et al:Clonal germinal center B cells function as a niche for T-cell lymphoma. Blood 140:1937-1950, 2022.
 

[III] 悪性リンパ腫の診断概論

P.126 掲載の参考文献
1) Swerdlow SH, Campo E, Arber DA, et al:Response to "The WHO classification of haematolymphoid tumours"(Editorial). Leukemia 36:2748-2749, 2022.
 
2) Cree IA:The WHO Classification of Haematolymphoid Tumours. Leukemia 36:1701-1702, 2022.
PubMed
3) Campo E, Jaffe ES, Cook JR, et al:The International Consensus Classification of Mature Lymphoid Neoplasms:a report from the Clinical Advisory Committee. Blood 140:1229-1253, 2022.
PubMed
4) Alaggio R, Amador C, Anagnostopoulos I, et al:The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours:Lymphoid Neoplasms. Leukemia 36:1720-1748, 2022.
PubMed
5) Carlsen ED, Swerdlow SH, Cook JR, et al:Class-switched Primary Cutaneous Marginal Zone Lymphomas Are Frequently IgG4-positive and Have Features Distinct From IgM-positive Cases. Am J Surg Pathol 43:1403-1412, 2019.
PubMed
6) Willemze R, Cerroni L, Kempf W, et al:The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood 133:1703-1714, 2019.
PubMed
7) Maurus K, Appenzeller S, Roth S, et al:Panel Sequencing Shows Recurrent Genetic FAS Alterations in Primary Cutaneous Marginal Zone Lymphoma. J Invest Dermatol 138:1573-1581, 2018.
PubMed
8) Takeuchi K, Yokoyama M, Ishizawa S, et al:Lymphomatoid gastropathy:a distinct clinicopathologic entity of self-limited pseudomalignant NK-cell proliferation. Blood 116:5631-5637, 2010.
PubMed
9) Mansoor A, Pittaluga S, Beck PL, et al:NK-cell enteropathy:a benign NK-cell lymphoproliferative disease mimicking intestinal lymphoma:clinicopathologic features and follow-up in a unique caseseries. Blood 117:1447-1452, 2011.
 
10) Xiao W, Gupta GK, Yao J, et al:Recurrent somatic JAK3 mutations in NK-cell enteropathy. Blood 134:986-991, 2019.
PubMed
11) Asano N, Suzuki R, Kagami Y, et al:Clinicopathologic and prognostic significance of cytotoxic molecule expression in nodal peripheral T-cell lymphoma, unspecified. Am J Surg Pathol 29:1284-1293, 2005.
PubMed
12) Takahashi E, Asano N, Li C, et al:Nodal T/NK-cell lymphoma of nasal type:a clinicopathological study of six cases. Histopathology 52:585-596, 2008.
PubMed
13) Kato S, Takahashi E, Asano N, et al:Nodal cytotoxic molecule(CM)-positive Epstein-Barr virus(EBV)-associated peripheral T cell lymphoma(PTCL):a clinicopathological study of 26 cases. Histopathology 61:186-199, 2012.
PubMed
14) Hori J, Yamaguchi T, Keino H, et al:Immune privilege in corneal transplantation. Prog Retin Eye Res 72:100758, 2019.
PubMed
15) Booman M, Douwes J, Legdeur MC, et al:From brain to testis:immune escape and clonal selection in a B cell lymphoma with selective outgrowth in two immune sanctuaries [correction of sanctuariesy]. Haematologica 92:e69-71, 2007.
 
16) Ascoli V, Lo Coco F, Torelli G, et al:Human herpesvirus 8-associated primary effusion lymphoma in HIV--patients:a clinicopidemiologic variant resembling classic Kaposi's sarcoma. Haematologica 87:339-343, 2002.
PubMed
17) Kaji D, Ota Y, Sato Y, et al:Primary human herpesvirus 8-negative effusion-based lymphoma:a large B-cell lymphoma with favorable prognosis. Blood Adv 4:4442-4450, 2020.
 
18) Marafioti T, Jones M, Facchetti F, et al:Phenotype and genotype of interfollicular large B cells, a subpopulation of lymphocytes often with dendritic morphology. Blood 102:2868-2876, 2003.
 
19) Traverse-Glehen A, Pittaluga S, Gaulard P, et al:Mediastinal gray zone lymphoma:the missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma. Am J Surg Pathol 29:1411-1421, 2005.
 
20) Sarkozy C, Hung SS, Chavez EA, et al:Mutational landscape of gray zone lymphoma. Blood 137:1765-1776, 2021.
PubMed
21) Ishigaki T, Isobe M, Kobayashi S, et al:Development of peripheral T-cell lymphoma not otherwise specified in an HTLV-1 carrier. Int J Hematol 97:667-672, 2013.
PubMed
22) Takatori M, Sakihama S, Miyara M, et al:A new diagnostic algorithm using biopsy specimens in adult T-cell leukemia/lymphoma:combination of RNA in situ hybridization and quantitative PCR for HTLV-1. Mod Pathol 34:51-58, 2021.
PubMed
P.132 掲載の参考文献
1) 田丸淳一:病理診断. 日本内科学会雑誌 97:1537-1545, 2008.
 
2) 田丸淳一:リンパ節生検時期, 方法, 部位の選択. 日本臨牀 73:302-305, 2015.
 
3) ゲノム研究用病理組織検体取扱い規程(日本病理学会ゲノム病理組織取扱い規約委員会/ゲノム研究用試料に関する病理組織検体取扱いガイドライン審議会), 2016. [https://pathology.or.jp/genome/index.html]
 
4) Tamaru J, Hummel M, Zemlin M, et al:Hodgkin's disease with a B-cell phenotype often shows a VDJ rearrangement and somatic mutations in the VH genes. Blood 84:708-715, 1994.
 
5) Adam P, Baumann R, Schmidt J, et al:The BCL2 E17 and SP66 antibodies discriminate 2 immunophenotypically and genetically distinct subgroups of conventionally BCL2-"negative" grade1/2 follicular lymphomas. Hum Pathol 44:1817-1826, 2013.
 
6) Mozos A, Royo C, Hartmann E, et al:SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica 94:1555-1562, 2009.
PubMed
7) Alaggio R, Amador C, Anagnostopoulos I, et al:The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours:Lymphoid Neoplasms. Leukemia 36:1720-1748, 2022.
PubMed
8) Ventura RA, Martin-Subero JI, Jones M, et al:FISH analysis for the detection of lymphoma-associated chromosomal abnormalities in routine paraffin-embedded tissue. J Mol Diagn 8:141-151, 2006.
 
9) Riedell PA, Smith SM:Double hit and double expressors in lymphoma:Definition and treatment. Cancer 124:4622-4632, 2018.
PubMed
P.141 掲載の参考文献
1) Tsai AG, Engelhart AE, Hatmal MM, et al:Conformational variants of duplex DNA correlated with cytosine-rich chromosomal fragile sites. J Biol Chem 284:7157-7164, 2009.
 
2) Tsai AG, Lu H, Raghavan SC, et al:Human chromosomal translocations at CpG sites and a theoretical basis for their lineage and stage specificity. Cell 135:1130-1142, 2008.
 
3) Matsumoto Y, Nomura K, Matsumoto S, et al:Detection of t(14;18) in follicular lymphoma by dual-color fluorescence in situ hybridization on paraffin-embedded tissue sections. Cancer Genet Cytogenet 150:22-26, 2004.
PubMed
4) Raghavan SC, Chastain P, Lee JS, et al:Evidence for a triplex DNA conformation at the bcl-2 major breakpoint region of the t(14;18) translocation. J Biol Chem 280:22749-22760, 2005.
 
5) Nambiar M, Goldsmith G, Moorthy BT, et al:Formation of a G-quadruplex at the BCL2 major breakpoint region of the t(14;18) translocation in follicular lymphoma. Nucleic Acids Res 39:936-948, 2011.
 
6) Javadekar SM, Yadav R, Raghavan SC:DNA structural basis for fragility at peak III of BCL2 majorbreakpoint region associated with t(14;18) translocation. Biochim Biophys Acta Gen Subj 1862:649-659, 2018.
 
7) Raghavan SC, Swanson PC, Wu X, et al:A non-B-DNA structure at the Bcl-2 major breakpoint region is cleaved by the RAG complex. Nature 428:88-93, 2004.
 
8) Nambiar M, Raghavan SC:Mechanism of fragility at BCL2 gene minor breakpoint cluster regionduring t(14;18) chromosomal translocation. J Biol Chem 287:8688-8701, 2012.
 
9) Duquette ML, Pham P, Goodman MF, et al:AID binds to transcription-induced structures in c-MYCthat map to regions associated with translocation and hypermutation. Oncogene 24:5791-5798, 2005.
 
10) Greisman HA, Lu Z, Tsai AG, et al:IgH partner breakpoint sequences provide evidence that AID initiates t(11;14) and t(8;14) chromosomal breaks in mantle cell and Burkitt lymphomas. Blood 120:2864-2867, 2012.
 
11) Lieber MR:Mechanisms of human lymphoid chromosomal translocations. Nat Rev Cancer 16:387-398, 2016.
PubMed
12) Kirkham CM, Scott JNF, Wang X, et al:Cut-and-Run:A Distinct Mechanism by which V(D)J Recombination Causes Genome Instability. Mol Cell 74:584-597. e9, 2019.
 
13) Jager U, Bocskor S, Le T, et al:Follicular lymphomas' BCL-2/IgH junctions contain templated nucleotide insertions:novel insights into the mechanism of t(14;18) translocation. Blood 95:3520-3529, 2000.
PubMed
14) Raghavan SC, Hsieh CL, Lieber MR:Both V(D)J coding ends but neither signal end can recombine at the bcl-2 major breakpoint region, and the rejoining is ligase IV dependent. Mol Cell Biol 25:6475-6484, 2005.
 
15) Zhu C, Mills KD, Ferguson DO, et al:Unrepaired DNA breaks in p53-deficient cells lead to oncogenic gene amplification subsequent to translocations. Cell 109:811-821, 2002.
PubMed
P.148 掲載の参考文献
1) Flores-Montero J, Sanoja-Flores L, Paiva B, et al:Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia 31:2094-2103, 2017.
PubMed
2) 日本臨床検査標準協議会血液検査標準化検討委員会フローサイトメトリーワーキンググループ:フローサイトメトリーによる造血器腫瘍細胞表面抗原検査に関するガイドライン(JCCLS H2-P V1.0). 日本臨床検査標準協議会会誌 18:69-107, 2003.
 
3) Clinical and Laboratory Standards Institute:Clinical Flowcytometric Analysis of Neoplastic Hematolymphoid Cells;Approved Guideline-second edition(H43-A2), CLSI, Wayne PA, 2007.
 
4) van Dongen JJ, Lhermitte L, Bottcher S, et al:EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 26:1908-1975, 2012.
PubMed
5) Inaba T, Nishimura H, Saito J, et al:A case of CD45-negative diffuse large B-cell lymphoma in thyroid gland. Lab Hematol 14:12-14, 2008.
 
6) Morisako T, Shishido-Hara Y, Inaba T, et al:Primary CNS CD45-Negative T-cell lymphoma:the first pathologically confirmed case. J Neuropathol Exp Neurol 79:817-820, 2020.
 
7) 稲葉 亨, 松本和道, 抱 章子, ほか:FCM検査の標準化 検査所見の付け方, 留意点. 日本検査血液学会雑誌 24:166-174, 2023.
 
8) 稲葉 亨, 松本和道, 塚本 拓:B細胞性腫瘍. 臨床病理 68:207-213, 2020.
Medical*Online
9) Inaba T, Shimazaki C, Sumikuma T, et al:T-cell associated antigen-positive B-cell lymphoma. Leuk Lymphoma 42:1161-1171, 2001.
 
10) Ravandi F, Kantarjian H, Jones D, et al:Mature T-cell leukemias. Cancer 104:1808-1818, 2005.
PubMed
11) Foucar K:Mature T-cell leukemias including T-prolymphocytic leukemia, adult T-cell leukemia/lymphoma, and Sezary syndrome. Am J Clin Pathol 127:496-510, 2007.
PubMed
12) 石垣知寛, 小林誠一郎, 在家裕司, ほか:成人T細胞白血病(ATL)におけるフローサイトメトリー解析法の確立とその臨床応用～12カラーの病態解析から4カラーの臨床検査まで～. CytometryResearch 24:33-39, 2014.
 
13) 松下弘道, 有賀 祐, 池田千秋:マルチカラー解析の基礎. 日本検査血液学会雑誌 19:422-429, 2018.
 
14) 林田雅彦, 前川ふみよ, 本庄 原, ほか:悪性リンパ腫のマルチカラーフローサイトメトリー解析-炎症を背景にもつ MALT リンパ腫および AITL を中心に-. 日本検査血液学会雑誌 19:441-453, 2018.
 
15) Schuster SJ, Bishop MR, Tam CS, et al:Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med 380:45-56, 2019.
 
P.154 掲載の参考文献
1) Cheson BD, Fisher RI, Barrington SF, et al:Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma:the Lugano classification. J Clin Oncol32:3059-3068, 2014.
 
P.158 掲載の参考文献
1) Davis AR, Stone SL, Oran AR, et al:Targeted massively parallel sequencing of mature lymphoid neoplasms:assessment of empirical application and diagnostic utility in routine clinical practice. Mod Pathol 34:904-921, 2021.
PubMed
2) Yasuda T, Sanada M, Nishijima D, et al:Clinical utility of target capture-based panel sequencing in hematological malignancies:A multicenter feasibility study. Cancer Sci 111:3367-3378, 2020.
PubMed
3) Pastore A, Jurinovic V, Kridel R, et al:Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma:a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol 16:1111-1122, 2015.
 
4) Schmitz R, Wright GW, Huang DW, et al:Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. N Engl J Med 378:1396-1407, 2018.
PubMed
5) Morschhauser F, Tilly H, Chaidos A, et al:Tazemetostat for patients with relapsed or refractory follicular lymphoma:an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol 21:1433-1442, 2020.
PubMed
6) Lauer EM, Mutter J, Scherer F:Circulating tumor DNA in B-cell lymphoma:technical advances, clinical applications, and perspectives for translational research. Leukemia 36:2151-2164, 2022.
 
7) Kurtz DM, Scherer F, Jin MC, et al:Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. J Clin Oncol 36:2845-2853, 2018.
PubMed
8) Shimada K, Yoshida K, Suzuki Y, et al:Frequent genetic alterations in immune checkpoint-related genes in intravascular large B-cell lymphoma. Blood 137:1491-1502, 2021.
 
9) Gupta M, Burns EJ, Georgantas NZ, et al:A rapid genotyping panel for detection of primary central nervous system lymphoma. Blood 138:382-386, 2021.
PubMed
10) Bonzheim I, Giese S, Deuter C, et al:High frequency of MYD88 mutations in vitreoretinal B-cell lymphoma:a valuable tool to improve diagnostic yield of vitreous aspirates. Blood 126:76-79, 2015
PubMed

[IV] 悪性リンパ腫の予後予測因子

P.167 掲載の参考文献
1) International Non-Hodgkin's Lymphoma Prognostic Factors Project:A predictive model foraggressive non-Hodgkin's lymphoma. N Engl J Med 329:987-994, 1993.
 
2) Sehn LH, Berry B, Chhanabhai M, et al:The revised International Prognostic Index(R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109:1857-1861, 2007.
 
3) Zhou Z, Sehn LH, Rademaker AW, et al:An enhanced International Prognostic Index(NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood 123:837-842, 2014.
PubMed
4) Kobayashi T, Kuroda J, Yokota I, et al:The Kyoto Prognostic Index for patients with diffuse large B-cell lymphoma in the rituximab era. Blood Cancer J 6:e383, 2016.
 
5) Schmitz R, Wright GW, Huang DW, et al:Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. N Engl J Med 378:1396-1407, 2018.
PubMed
6) Wright GW, Huang DW, Phelan JD, et al:A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. Cancer Cell 37:551-568. e14, 2020.
 
7) Solal-Celigny P, Roy P, Colombat P, et al:Follicular lymphoma international prognostic index. Blood 104:1258-1265, 2004.
PubMed
8) Federico M, Bellei M, Marcheselli L, et al:Follicular lymphoma international prognostic index 2:a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 27:4555-4562, 2009.
PubMed
9) Pastore A, Jurinovic V, Kridel R, et al:Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma:a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol 16:1111-1122, 2015.
 
10) Bolen CR, Mattiello F, Herold M, et al:Treatment dependence of prognostic gene expression signatures in de novo follicular lymphoma. Blood 137:2704-2707, 2021.
PubMed
11) Mir F, Mattiello F, Grigg A, et al:Follicular Lymphoma Evaluation Index(FLEX):A new clinical prognostic model that is superior to existing risk scores for predicting progression-free survival and early treatment failure after frontline immunochemotherapy. Am J Hematol 95:1503-1510, 2020.
 
12) Mondello P, Fama A, Larson MC, et al:Lack of intrafollicular memory CD4 + T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma. Blood Cancer J 11:130, 2021.
PubMed
13) Tsukamoto T, Nakano M, Sato R, et al:High-risk follicular lymphomas harbour more somatic mutations including those in the AID-motif. Sci Rep 7:14039, 2017.
PubMed
14) Hoster E, Dreyling M, Klapper W, et al:A new prognostic index(MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 111:558-565, 2008.
PubMed
15) Thieblemont C, Cascione L, Conconi A, et al:A MALT lymphoma prognostic index. Blood 130:1409-1417, 2017.
PubMed
P.172 掲載の参考文献
1) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised Fourth Edition(ed by Swerdlow S, Campo E, Harris N, et al). IARC Press, Lyon, 2017.
 
2) Vose J, Armitage J, Weisenburger D, et al:International peripheral T-cell and natural killer/T-cell lymphoma study:pathology findings and clinical outcomes. J Clin Oncol 26:4124-4130, 2008.
PubMed
3) International Non-Hodgkin's Lymphoma Prognostic Factors Project:A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:987-994, 1993.
 
4) Gallamini A, Stelitano C, Calvi R, et al:Peripheral T-cell lymphoma unspecified(PTCL-U):a new prognostic model from a retrospective multicentric clinical study. Blood 103:2474-2479, 2004.
 
5) Went P, Agostinelli, Gallamini A, et al:Marker expression in peripheral T-cell lymphoma:a proposed clinical-pathologic prognostic score. J Clin Oncol 24:2472-2479, 2006.
 
6) Federico M, Bellei M, Marcheselli L, et al:Peripheral T cell lymphoma, not otherwise specified(PTCL-NOS). A new prognostic model developed by the International T cell Project Network. Br J Haematol 181:760-769, 2018.
 
7) Federico M, Rudiger T, Bellei A, et al:Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma:analysis of the international peripheral T-cell lymphoma project. J Clin Oncol 31:240-246, 2013.
 
8) Tokunaga T, Shimada K, Yamamoto K, et al:Retrospective analysis of prognostic factors for angioimmunoblastic T-cell lymphoma:a multicenter cooperative study in Japan. Blood 119:2837-2843, 2012.
PubMed
9) Vose JM:International Peripheral T-cell Lymphoma(PTCL) Clinical and Pathology Review Project:poor outcome by prognostic indices and lack of efficacy with anthracyclines. Blood 106:811, 2005.
 
10) Savage KJ, Harris NL, Vose JM, et al:ALK-anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified:report from the International Peripheral T-Cell Lymphoma Project. Blood 111:5496-5504, 2008.
 
11) Sibon D, Fournier M, Briere J, et al:Long-term outcome of adults with systemic anaplastic large cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte trials. J Clin Oncol 30:3939-3946, 2012.
 
12) Lee J, Suh C, Park YH, et al:Extranodal natural killer T-cell lymphoma, nasal-type:a prognostic model from a retrospective multicenter study. J Clin Oncol 24:612-618, 2006.
 
13) Kim TM, Park YH, Lee SY, et al:Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage I(E)/II(E) extranodal NK/T-cell lymphoma, nasal type. Blood106:3785-3790, 2005.
 
14) Kim SJ, Yoon DH, Jaccard A, et al:A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment:a multicentre, retrospective analysis. Lancet Oncol 17:389-400, 2016.
PubMed
15) Yamaguchi M, Suzuki R, Oguchi M, et al:Treatments and Outcomes of Patients With Extranodal Natural Killer/T-Cell Lymphoma Diagnosed Between 2000 and 2013:A Cooperative Study in Japan. J Clin Oncol 35:32-39, 2017.
PubMed
16) Shimoyama M:Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group(1984-87). Br J Haematol 79:428-437, 1991.
 
17) Katsuya H, Ishitsuka K, Utsunomiya A, et al:Treatment and survival among 1594 patients with ATL. Blood 126:2570-2577, 2015.
PubMed
18) Fukushima T, Nomura S, Shimoyama M, et al:Japan Clinical Oncology Group(JCOG) prognostic index and characterization of long-term survivors of aggressive adult T-cell leukaemia-lymphoma(JCOG0902A). Br J Haematol 166:739-748, 2014.
PubMed
19) Fuji S, Yamaguchi T, Inoue Y, et al:Development of a modified prognostic index for patients with aggressive adult T-cell leukemia-lymphoma aged 70 years or younger:possible risk-adapted management strategies including allogeneic transplantation. Haematologica 102:1258-1265, 2017.
PubMed
20) Katsuya H, Shimokawa M, Ishitsuka K, et al:Prognostic index for chronic-and smoldering-type adult T-cell leukemia-lymphoma. Blood 130:39-47, 2017.
PubMed
21) de Baaij LR, Berkhof J, van de Water JM, et al:A New and Validated Clinical Prognostic Model(EPI) for Enteropathy-Associated T-cell Lymphoma. Clin Cancer Res 21:3013-3019, 2015.
PubMed
22) Mead M, Cederleuf H, Bjorklund M, et al:Impact of comorbidity in older patients with peripheral T-cell lymphoma:an international retrospective analysis of 891 patients. Blood Adv 6:2120-2128, 2022.
PubMed
23) El-Galaly TC, Pedersen MB, Hutchings M, et al:Utility of interim and end-of-treatment PET/CT in peripheral T-cell lymphomas:A review of 124 patients. Am J Hematol 90:975-980, 2015.
PubMed
24) Advani RH, Skrypets T, Civallero M, et al:Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma:final report from the international T-cell Project. Blood 138:213-220, 2021.
PubMed
P.178 掲載の参考文献
1) Makita S, Maruyama D, Miyagi Maeshima A, et al:Clinical features and outcomes of 139 Japanese patients with Hodgkin lymphoma. Int J Hematol 104:236-244, 2016.
 
2) Armitage JO:Early-stage Hodgkin's lymphoma. N Engl J Med 363:653-662, 2010.
PubMed
3) Meyer RM, Gospodarowicz MK, Connors JM, et al:Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma:National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 23:4634-4642, 2005.
 
4) ホジキンリンパ腫(HL). 造血器腫瘍診療ガイドライン2018年版補訂版(一般社団法人日本血液学会 編), p297, 金原出版, 2020.
 
5) Armitage JO:Early-stage Hodgkin's lymphoma. N Engl J Med 363:653-662, 2010.
PubMed
6) Hasenclever D, Diehl V:A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 339:1506-1514, 1998.
 
7) Moccia AA, Donaldson J, Chhanabhai M, et al:International Prognostic Score in advanced-stage Hodgkin's lymphoma:altered utility in the modern era. J Clin Oncol 30:3383-3388, 2012.
PubMed
8) Gallamini A, Hutchings M, Rigacci L, et al:Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma:a report from a joint Italian-Danish study. J Clin Oncol 25:3746-3752, 2007.
PubMed
9) Connors JM, Jurczak W, Straus DJ, et al:Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. N Engl J Med 378:331-344, 2018.
PubMed
10) Rodday AM, Parsons SK, Upshaw JN, et al:The Advanced-Stage Hodgkin lymphoma International Prognostic Index:Development and validation of a clinical prediction model from the HoLISTIC consortium. J Clin Oncol, 2022.(DOI:10.1200/JCO. 22.02473)
 
11) Moskowitz CH, Nademanee A, Masszi T, et al:Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression(AETHERA):a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 385:1853-1862, 2015.
 
12) Chan FC, Mottok A, Gerrie AS, et al:Prognostic Model to Predict Post-Autologous Stem-Cell Transplantation Outcomes in Classical Hodgkin Lymphoma. J Clin Oncol 35:3722-3733, 2017.
PubMed
13) Spina V, Bruscaggin A, Cuccaro A, et al:Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma. Blood 131:2413-2425, 2018.
PubMed
P.184 掲載の参考文献
1) Gleeson M, Counsell N, Cunningham D, et al:Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era:results of the UK NCRI R-CHOP-14 versus 21 trial. Ann Oncol 28:2511-2516, 2017.
PubMed
2) Schmitz N, Zeynalova S, Nickelsen M, et al:CNS International Prognostic Index:A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP. J Clin Oncol 34:3150-3156, 2016.
 
3) El-Galaly TC, Villa D, Michaelsen TY, et al:The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma:An international multicenter study of 1532 patients treated with chemoimmunotherapy. Eur J Cancer75:195-203, 2017.
 
4) Kridel R, Telio D, Villa D, et al:Diffuse large B-cell lymphoma with testicular involvement:outcome and risk of CNS relapse in the rituximab era. Br J Haematol 176:210-221, 2017.
PubMed
5) Tomita N, Yokoyama M, Yamamoto W, et al:Central nervous system event in patients with diffuse large B-cell lymphoma in the rituximab era. Cancer Sci 103:245-251, 2012.
PubMed
6) Klanova M, Sehn LH, Bence-Bruckler I, et al:Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL. Blood 133:919-926, 2019.
PubMed
7) Miyazaki K, Yamaguchi M, Suzuki R, et al:CD5-positive diffuse large B-cell lymphoma:a retrospective study in 337 patients treated by chemotherapy with or without rituximab. Ann Oncol 22:1601-1607, 2011.
PubMed
8) Shimada K, Matsue K, Yamamoto K, et al:Retrospective analysis of intravascular large B-cell lymphoma treated with rituximab-containing chemotherapy as reported by the IVL study group in Japan. J Clin Oncol 26:3189-3195, 2008.
 
9) Eyre TA, Djebbari F, Kirkwood AA, et al:Efficacy of central nervous system prophylaxis with stand-alone intrathecal chemotherapy in diffuse large B-cell lymphoma patients treated with anthracycline-based chemotherapy in the rituximab era:a systematic review. Haematologica 105:1914-1924, 2020.
 
10) Wilson MR, Eyre TA, Kirkwood AA, et al:Timing of high-dose methotrexate CNS prophylaxis in DLBCL:a multicenter international analysis of 1384 patients. Blood 139:2499-2511, 2022.
PubMed
11) Lin Z, Chen X, Liu L, et al:The role of central nervous system(CNS) prophylaxis in preventing DLBCL patients from CNS relapse:A network meta-analysis. Crit Rev Oncol Hematol 176:103756, 2022.
 
12) Miyazaki K, Asano N, Yamada T, et al:DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma:a single-arm, open-label, phase II study. Haematologica 105:2308-2315, 2020.
PubMed
13) Shimada K, Yamaguchi M, Atsuta Y, et al:Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma(PRIMEUR-IVL):a multicentre, single-arm, phase 2 trial. Lancet Oncol 21:593-602, 2020.
 
14) Zayac AS, Evens AM, Danilov A, et al:Outcomes of Burkitt lymphoma with central nervous system involvement:evidence from a large multicenter cohort study. Haematologica 106:1932-1942, 2021.
PubMed
15) Kim H, Jeong H, Yamaguchi M, et al:Prediction and prevention of central nervous system relapse in patients with extranodal natural killer/T-cell lymphoma. Blood 136:2548-2556, 2020.
 

[V] 病型各論 - 疾患概念・疫学・分類・臨床像・診断・治療・予後・話題 -

P.193 掲載の参考文献
1) Engert A, Plutschow A, Eich HT, et al:Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 363:640-652, 2010.
PubMed
2) Eich HT, Diehl V, Gorgen H, et al:Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma:final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 28:4199-4206, 2010.
 
3) Meyer RM, Gospodarowicz MK, Connors JM, et al:ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. N Engl J Med 366:399-408, 2012.
PubMed
4) Borchmann P, Plutschow A, Kobe C, et al:PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma(GHSG HD17):a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 22:223-234, 2021.
PubMed
5) LaCasce AS, Dockter T, Ruppert AS, et al:Positron Emission Tomography-Adapted Therapy in Bulky Stage I/II Classic Hodgkin Lymphoma:CALGB 50801(Alliance). J Clin Oncol 41:1023-1034, 2023.
 
6) Johnson P, Federico M, Kirkwood A, et al:Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma. N Engl J Med 374:2419-2429, 2016.
PubMed
7) Andre MPE, Girinsky T, Federico M, et al:Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma:Final Results of the Randomized EORTC/LYSA/FIL H10 Trial. J Clin Oncol 35:1786-1794, 2017.
 
8) Press OW, Li H, Schoder H, et al:US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging:Southwest Oncology Group S0816. J Clin Oncol 34:2020-2027, 2016.
 
9) Kusumoto S, Munakata W, Machida R, et al:Interim PET-guided ABVD or ABVD/escalated BEACOPP regimen for newly diagnosed advanced-stage classic Hodgkin lymphoma(JCOG1305, INNOVATE-HL study). Blood 14(Suppl 1):3718-3721, 2022.
 
10) Connors JM, Jurczak W, Straus DJ, et al:Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. N Engl J Med 378:331-344, 2018.
PubMed
11) Ansell SM, Radford J, Connors JM, et al:Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma. N Engl J Med 387:310-320, 2022.
 
12) Longo DL, Armitage JO:A Better Treatment for Advanced-Stage Hodgkin's Lymphoma? N Engl JMed 387:370-372, 2022.
 
13) Evens AM, Connors JM, Younes A, et al:Older patients(aged360 years) with previously untreated advanced-stage classical Hodgkin lymphoma:a detailed analysis from the phase III ECHELON-1 study. Haematologica 107:1086-1094, 2022.
PubMed
14) Moskowitz CH, Nademanee A, Masszi T, et al:Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression(AETHERA):a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 385:1853-1862, 2015.
 
15) Casadei B, Argnani L, Morigi A, et al:Effectiveness of chemotherapy after anti-PD-1 blockade failure for relapsed and refractory Hodgkin lymphoma. Cancer Med 9:7830-7836, 2020.
PubMed
P.196 掲載の参考文献
1) Li W:Chapter 1. The 5th Edition of the World Health Organization Classification of Hematolymphoid Tumors In:Leukemia [Internet](ed by Li W), Exon Publications, Brisbane, 2022 Oct 16.
 
2) Maitra A, McKenna RW, Weinberg AG, et al:Precursor B-cell lymphoblastic lymphoma. A study of nine cases lacking blood and bone marrow involvement and review of the literature. Am J Clin Pthol 115:868-875, 2001.
 
3) Coyaud E, Struski S, Prade N, et al:Wide diversity of PAX5 alterations in B-ALL:a Groupe Francophone de Cytogenetique Hematologique study. Blood 115:3089-3097, 2010.
 
4) Parker C, Krishnan S, Hamadeh L, et al:Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukameia with late bone marrow relapses:long-term follow-up of the ALLR3 open-label randomized trial. Lancet Haematol 6:e204-e216, 2019.
PubMed
5) Suzuki K, Okuno Y, Kawashima N, et al:MEF2D-BCL9 Fusion Gene Is Associated With High-Risk Acute B-Cell Precursor Lymphoblastic Leukemia in Adolescents. J Clin Oncol 34:3451-3459, 2016.
PubMed
6) Yasuda T, Tsuzuki S, Kawazu M, et al:Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults. Nat Genet 48:569-574, 2016.
 
7) Qian M, Zhang H, Kham SK, et al:Whole-transcriptome sequencing identifies a distinct subtype of acute lymphoblastic leukemia with predominant genomic abnormalities of EP300 and CREBBP. Genome Res 27:185-195, 2017.
PubMed
8) A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 89:3909-3918, 1997.
 
9) Soslow RA, Baergen RN, Warnke RA:B-lineage lymphoblastic lymphoma is a clinicopathologic entity distinct from other histologically similar aggressive lymphomas with blastic morphology. Cancer 85:2648-2654, 1999.
PubMed
10) 小児慢性特定疾患情報センター:Bリンパ芽球性リンパ腫. バージョン1.0 更新日:2014年10月1日(文責 日本小児血液・がん学会)[https://www.shouman.jp/disease/details/01_03_020/]
 
11) Lin P, Jones D, Dorman DM, et al:Precursor B-cell lymphoblastic lymphoma:a predominantly extranodal tumor with low propensity for leukemic involvement. Am J Surg Pathol 24:1480-1490, 2000.
 
12) Sander CA, Jaffe ES, Gebhardt FC, et al:Mediastinal lymphoblastic lymphoma with an immature B-cell immunophenotype. Am J Surg Pathol 16:300-305, 1992.
PubMed
13) Anderson BP, Metz CM:B-cell lymphoblastic lymphoma of the Paranasal Sinuses:A Case Study of a Rare Clinical Entity. Cureus 14:e31565, 2022.
PubMed
14) Thomas DA, O'Brien S, Cortes J, et al:Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood 104:1624-1630, 2004.
PubMed
P.203 掲載の参考文献
1) Campo E, et al:Chronic lymphocytic leukaemia/small lymphocytic lymphoma. In:WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed, Revised ed(ed by Swerdlow SH, Campo E, Harris NL, et al), p216-221, IARC Press, Lyon, 2017.
 
2) Hallek M, Cheson BD, Catovsky D, et al:iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 131:2745-2760, 2018.
PubMed
3) 造血器腫瘍診療ガイドライン2018年版補訂版(日本血液学会 編), p121-143, 金原出版, 2020.
 
4) Ruchlemer R, Polliack A:Geography, ethnicity and "roots" in chronic lymphocytic leuk emia. LeukLymphoma 54:1142-1150, 2013.
 
5) Redaelli A, Laskin BL, Stephens JM, et al:The clinical and epidemiological burden of chronic lymphocytic leukaemia. Eur J Cancer Care(Engl) 13:279-287, 2004.
PubMed
6) Eichhorst B, Robak T, Montserrat E, et al:Chronic lymphocytic leukaemia:ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(Suppl 5):v78-v84, 2015.
 
7) NCCN Clinical Practice Guidelines in Oncology. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Version 2, 2020.
PubMed
8) 瀧澤 淳:慢性リンパ性白血病-病態解明の進歩と治療の現在-. 臨床血液 58:471-479, 2017.
 
9) Yatabe Y, Suzuki R, Tobinai K, et al:Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma:a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma. Blood 95:2253-2261, 2000.
 
10) Dufresne SD, Felgar RE, Sargent RL, et al:Defining the borders of splenic marginal zone lymphoma:a multiparameter study. Hum Pathol 41:540-551, 2010.
PubMed
11) Thorns C, Kalies K, Fischer U, et al:Significant high expression of CD23 in follicular lymphoma of the inguinal region. Histopathology 50:716-719, 2007.
PubMed
12) Matutes E, Owusu-Ankomah K, Morilla R, et al:The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 8:1640-1645, 1994.
PubMed
13) Rawstron AC, Kreuzer KA, Soosapilla A, et al:Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry:An European Research Initiative on CLL(ERIC) & European Society for Clinical Cell Analysis(ESCCA) Harmonisation project. Cytometry B Clin Cytom 94:121-128, 2018.
PubMed
14) Takizawa J, Izutsu K, Nagai H, et al:Real World Treatment Practices for Chronic Lymphocytic Leukemia in Japan:An Observational Database Research Study(CLIMBER-DBR). J Clin Exp Hematop 61:126-134, 2021.
PubMed
15) Parikh SA:Chronic lymphocytic leukemia treatment algorithm 2018. Blood Cancer J 8:93, 2018.
PubMed
16) Burger JA, Barr PM, Robak T, et al:Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL:5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia 34:787-798, 2020.
PubMed
17) Bewarder M, Stilgenbauer S, Thurner L, et al:Current Treatment Options in CLL. Cancers 13(Basel):2468, 2021.
PubMed
18) Byrd JC, Hillmen P, Ghia P, et al:Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia:Results of the First Randomized Phase III Trial. J Clin Oncol 39:3441-3452, 2021.
PubMed
19) Seymour JF, Kipps TJ, Eichhorst B, et al:Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. N Engl J Med 378:1107-1120, 2018.
 
20) Mukkamalla SKR, Taneja A, Malipeddi D, et al:Chronic Lymphocytic leukemia. StatPearls[Internet], NCBI Bookshelf, 2022.
 
21) Sharman JP, Egyed M, Jurczak W, et al:Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia(ELEVATE TN):a randomised, controlled, phase 3 trial. Lancet 395:1278-1291, 2020.
 
P.209 掲載の参考文献
1) Campo E, et al:B-cell prolymphocytic leukemia. In:WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed,(ed by Swedlow SH, Campo E, Harris NL, et al), p183-184, IARC, Lyon, 2008.
 
2) Alaggio R, Amador C, Anagnostopoulos I, et al:The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours:Lymphoid Neoplasms. Leukemia 36:1720-1748, 2022.
PubMed
3) Campo E, Jaffe ES, Cook JR, et al:The International Consensus Classification of Mature Lymphoid Neoplasms:a report from the Clinical Advisory Committee. Blood 140:1229-1253, 2022
PubMed
4) Galton DA, Goldman JM, Wiltshaw E, et al:Prolymphocytic leukaemia. Brit J Haematol 27:7-23, 1974.
 
5) Melo JV, Catovsky D, Galton DA, et al:The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia. 1. Clinical and laboratory features of 300 patients and characteriza-tion of an intermediate group. Brit J Haematol 63:377-387, 1986.
 
6) Schlette E, Bueso-Ramos C, Giles F, et al:Mature B-cell leukemias with more than 55% prolymphocytes. A heterogeneous group that includes an unusual variant of mantle cell lymphoma. Am J Clin Pathol 115:571-581, 2001.
PubMed
7) Ruchlemer R, Parry-Jones N, Brito-Babapulle V, et al:B-prolymphocytic leukaemia with t(11;14) revisited:a splenomegalic form of mantle cell lymphoma evolving with leukaemia. Br J Haematol125:330-336, 2004.
 
8) Hoehn D, Miranda RN, Kanagal-Shamanna R, et al:Splenic B-cell lymphomas with more than 55% prolymphocytes in blood:evidence for prolymphocytoid transformation. Hum Pathol 43:1828-1838, 2012.
PubMed
9) Cai J, Qing X:Splenic marginal zone lymphoma with increased prolymphocytes. Blood 137:31502021.
 
10) Matutes E, Owusu-Ankomah K, Morilla R, et al:The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 8:1640-1645, 1994.
PubMed
11) Cross M, Dearden C:B and T cell prolymphocytic leukaemia. Best Pract Res Clin Haematol 32:217-228, 2019.
 
12) Chapiro E, Pramil E, Diop M, et al:Genetic characterization of B-cell prolymphocytic leukemia:a prognostic model involving MYC and TP53. Blood 134:1821-1831, 2019.
PubMed
13) Davi F, Maloum K, Michel A, et al:High frequency of somatic mutations in the VH genes expressed in prolymphocytic leukemia. Blood 88:3953-3961, 1996.
PubMed
14) Del Giudice I, Davis Z, Matutes E, et al:IgVH genes mutation and usage, ZAP-70 and CD38 expression provide new insights on B-cell prolymphocytic leukemia(B-PLL). Leukemia 20:1231-1237, 2006.
 
15) Del Giudice I, Osuji N, Dexter T, et al:B-cell prolymphocytic leukemia and chronic lymphocytic leukemia have distinctive gene expression signatures. Leukemia 23:2160-2167, 2009.
PubMed
16) van der Velden VH, Hoogeveen PG, de Ridder D, et al:B-cell prolymphocytic leukemia:a specific subgroup of mantle cell lymphoma. Blood 124:412-419, 2014.
PubMed
17) Dearden C:How I treat prolymphocytic leukemia. Blood 120:538-551, 2012.
 
18) Eyre TA, Fox CP, Boden A, et al:Idelalisib-rituximab induces durable remissions in TP53 disrupted B-PLL but results in significant toxicity:updated results of the UK-wide compassionate useprogramme. Br J Haematol 184:667-671, 2019.
PubMed
19) Gordon MJ, Raess PW, Young K, et al:Ibrutinib is an effective treatment for B-cell prolymphocytic leukaemia. Br J Haematol 179:501-503, 2017.
PubMed
20) Patil N, Went RG:Venetoclax is an option in B-cell prolymphocytic leukaemia following progression on B-cell receptor pathway inhibitors. Br J Haematol 186:e80-e82, 2019.
 
21) Chen LY, Eyre TA:Venetoclax induces deep and durable minimal residual disease-negative remission in high-risk TP53 disrupted B prolymphocytic leukaemia. Eur J Haematol 109:590-592, 2022.
PubMed
22) Kalaycio ME, Kukreja M, Woolfrey AE, et al:Allogeneic hematopoietic cell transplant for prolymphocytic leukemia. Biol Blood Marrow Transplant 16:543-547, 2010.
PubMed
P.214 掲載の参考文献
1) Alaggio R, Amador C, Anagnostopoulos I, et al:The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours:Lymphoid Neoplasms. Leukemia 36:1720-1748, 2022.
PubMed
2) Swedlow SH, Campo E, Harris NL, et al(ed):WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues, 4th ed, International Agency for Research on Cancer, Lyon, 2017.
 
3) Sutcliffe MJ, Shuster JJ, Sather HN, et al:High concordance from independent studies by the Children's Cancer Group(CCG) and Pediatric Oncology Group(POG) associating favorable prognosis with combined trisomies 4, 10, and 17 in children with NCI Standard-Risk B-precursor Acute Lymphoblastic Leukemia:a Children's Oncology Group(COG) initiative. Leukemia 19:734-740, 2005.
 
4) Meyer JA, Zhou D, Mason CC, et al:Genomic characterization of pediatric B-lymphoblastic lymphoma and B-lymphoblastic leukemia using formalin-fixed tissues. Pediatr Blood Cancer 64:e26363, 2017.
 
5) Holmfeldt L, Wei L, Diaz-Flores E, et al:The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet 45:242-252, 2013.
PubMed
6) Moorman AV, Ensor HM, Richards SM, et al:Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia:results from the UK Medical Research Council ALL97/99 randomised trial. Lancet Oncol 11:429-438, 2010.
PubMed
7) Harrison CJ, Moorman AV, Schwab C, et al:An international study of intrachromosomal amplification of chromosome 21(iAMP21):cytogenetic characterization and outcome. Leukemia 28:1015-1021, 2014.
 
8) Yamada C, Shimomura Y, Kamijyo K, et al:BCR/ABL1-positive B-lymphoblastic Lymphoma Successfully Treated with Dasatinib-combined Chemotherapy. Intern Med 60:3149-3153, 2021.
 
9) Tomii T, Imamura T, Tanaka K, et al:Leukemic cells expressing NCOR1-LYN are sensitive to dasatinib in vivo in a patient-derived xenograft mouse model. Leukemia 35:2092-2096, 2021.
 
10) Mayumi A, Tomii T, Kanayama T, et al:The combination of ruxolitinib and Bcl-2/Mcl-1 inhibitors has a synergistic effect on leukemic cells carrying a SPAG9::JAK2 fusion. Cancer Gene Ther 29:1930-1938, 2022.
 
11) Isobe T, Takagi M, Sato-Otsubo A, et al:Multi-omics analysis defines highly refractory RAS burdened immature subgroup of infant acute lymphoblastic leukemia. Nat Commun 13:4501, 2022.
PubMed
12) Mater DV, Goodman BK, Wang E, et al:MLL duplication in a pediatric patient with B-cell lymphoblastic lymphoma. J Pediatr Hematol Oncol 34:e120-e123, 2012.
 
13) Lilljebjorn H, Henningsson R, Hyrenius-Wittsten A, et al:Identification of ETV6-RUNX1-like and DUX4-rearranged subtypes in paediatric B-cell precursor acute lymphoblastic leukaemia. Nat Commun 7:11790, 2016.
PubMed
14) Fischer U, Forster M, Rinaldi A, et al:Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options. Nat Genet47:1020-1029, 2015.
PubMed
15) Tomizawa D, Miyamura T, Imamura T, et al:A risk-stratified therapy for infants with acute lymphoblastic leukemia:a report from the JPLSG MLL-10 trial. Blood 136:1813-1823, 2020.
PubMed
P.220 掲載の参考文献
1) Bouroncle BA, Wiseman BK, Doan CA:Leukemic reticuloendotheliosis. Blood 13:609-630, 1958.
PubMed
2) Schrek R, Donnelly WJ:"Hairy" cells in blood in lymphoreticular neoplastic disease and "flagellated" cells of normal lymph nodes. Blood 27:199-211, 1966.
PubMed
3) Basso K, Liso A, Tiacci E, et al:Gene expression profiling of hairy cell leukemia reveals a phenotype related to memory B cells with altered expression of chemokine and adhesion receptors. J Exp Med199:59-68, 2004.
 
4) Tiacci E, Trifonov V, Schiavoni G, et al:BRAF mutations in hairy-cell leukemia. N Engl J Med 364:2305-2315, 2011.
PubMed
5) Zhang X, Machii T, Matsumura I, et al:Constitutively activated Rho guanosine triphosphatases regulate the growth and morphology of hairy cell leukemia cells. Int J Hematol 77:263-273, 2003.
PubMed
6) 柴山浩彦:ヘアリーセル白血病. 造血器腫瘍アトラス(第5版), p488-494, 日本医事新報社, 2016.
 
7) Matutes E, Wotherspoon A, Brito-Babapulle V, et al:The natural history and clinico-pathological features of the variant form of hairy cell leukemia. Leukemia 15:184-186, 2001.
PubMed
8) Machii T, Tokumine Y, Inoue R, et al:Predominance of a distinct subtype of hairy cell leukemia in Japan. Leukemia 7:181-186, 1993.
PubMed
9) Maevis V, Mey U, Schmidt-Wolf G, et al:Hairy cell leukemia:short review, today's recommendations and outlook. Blood Cancer J 4:e184, 2014.
 
10) Grever M, Andritsos L, Banerji V, et al:Hairy cell leukemia and COVID-19 adaptation of treatment guidelines. Leukemia 35:1864-1872, 2021.
PubMed
11) Dietrich S, Glimm H, Andrulis M, et al:BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med 366:2038-2040, 2012.
PubMed
12) Robak T, Wolska A, Robak P:Potential breakthroughs with investigational drugs for hairy cell leukemia. Expert Opin Investig Drugs 24:1419-1431, 2015.
PubMed
13) Salam L, Abdel-Wahab O:Hairy cell leukemia:update and current therapeutic approach. Curr Opin Hematol 22:355-361, 2015.
 
14) NCCN Guidelines Version 1. 2023. Hairy Cell Leukemia. [https://www.nccn.org/professionals/physician_gls/pdf/hairy_cell.pdf]
 
P.224 掲載の参考文献
1) Swerdlow SH, Cook JR, Sohani AR, et al:Lymphoplasmacytic lymphoma. In:World health Organization Classification of Tumour of Hematopoietic and Lymphoid Tissues 4th ed(ed by Swerdlow SH, Campo E, Harris NL, et al) p232-235, JARC Press, Lyon, 2017.
 
2) Sekiguchi N:Waldenstrom macroglobulinemia:Japanese perception. Rinsho Ketsueki 60:988-997, 2019.
PubMed
3) Treon SP, Xu L, Yang G, et al:MYD88 L265P somatic mutation in Waldenstrom's macroglobuline-mia. N Engl J Med 367:826-833, 2012.
 
4) Hunter ZR, Xu L, Yang G, et al:The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood 123:1637-1646, 2014.
 
5) Poulain S, Roumier C, Venet-Caillault A, et al:Genomic Landscape of CXCR4 Mutations in Waldenstrom Macroglobulinemia. Clin Cancer Res 22:1480-1488, 2016.
PubMed
6) Treon SP, Cao Y, Xu L, et al:Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. Blood 123:2791-2796, 2014.
PubMed
7) Kofides A, Hunter ZR, Xu L, et al:Diagnostic Next-generation Sequencing Frequently Fails to Detect MYD88L265Pin Waldenstrom Macroglobulinemia. Hemasphere 5:e624, 2021.
PubMed
8) Gustine JN, Xu L, Yang G, et al:Bone marrow involvement and subclonal diversity impairs detection of mutated CXCR4 by diagnostic next-generation sequencing in Waldenstrom macroglobulinaemia. Br J Haematol 194:730-733, 2021.
 
9) National Comprehensive Cancer Network:NCCN Clinical Practice Guidelines in Oncology. Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma. Version 1.2023. [https://www.nccn.org/store/login/login.aspx?ReturnURL=https://www.nccn.org/professionals/physi-cian_gls/pdf/waldenstroms]
 
10) リンパ形質細胞性リンパ腫/ワルデンシュトレームマクログロブリン血症(LPL/WM). 造血器腫瘍診療ガイドライン2018年版補訂版(日本血液学会 編), p208-214, 金原出版, 2020.
 
11) Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al:Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol 25:3344-3349, 2007.
PubMed
12) Rummel MJ, Niederle N, Maschmeyer G, et al:Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas:an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381:1203-1210, 2013.
PubMed
13) Treon SP, Ioakimidis L, Soumerai JD, et al:Primary therapy of Waldenstrom macroglobulinemia with bortezomib, dexamethasone, and rituximab:WMCTG clinical trial 05-180. J Clin Oncol 27:3830-3835, 2009.
PubMed
14) Treon SP, Tripsas CK, Meid K, et al:Ibrutinib in previously treated Waldenstrom's macroglobuline-mia. N Engl J Med 372:1430-1440, 2015.
 
15) Treon SP, Gustine J, Meid K, et al:Ibrutinib Monotherapy in Symptomatic, Treatment-Naive Patients With Waldenstrom Macroglobulinemia. J Clin Oncol 36:2755-2761, 2018.
PubMed
16) Dimopoulos MA, Tedeschi A, Trotman J, et al:Phase 3 Trial of Ibrutinib plus Rituximab in Waldenstrom's Macroglobulinemia. N Engl J Med 378:2399-2410, 2018.
PubMed
17) Tam CS, Opat S, D'Sa S, et al:A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstrom macroglobulinemia:the ASPEN study. Blood 136:2038-2050, 2020.
PubMed
18) Owen RG, McCarthy H, Rule S, et al:Acalabrutinib monotherapy in patients with Waldenstrom macroglobulinemia:a single-arm, multicentre, phase 2 study. Lancet Haematol 7:e112-e121, 2020.
PubMed
19) Sekiguchi N, Rai S, Munakata W, et al:A multicenter, open-label, phase II study of tirabrutinib(ONO/GS-4059) in patients with Waldenstrom's macroglobulinemia. Cancer Sci 111:3327-3337, 2020.
PubMed
20) Sekiguchi N, Rai S, Munakata W, et al:Two-year outcomes of tirabrutinib monotherapy in Waldenstrom's macroglobulinemia. Cancer Sci 113:2085-2096, 2022.
PubMed
21) Castillo JJ, Abeykoon JP, Gustine JN, et al:Partial response or better at six months is prognostic of superior progression-free survival in Waldenstrom macroglobulinaemia patients treated with ibrutinib. Br J Haematol 192:542-550, 2021.
PubMed
22) Abushukair H, Syaj S, Ababneh O, et al:First-versus second-generation Bruton tyrosine kinase inhibitors in Waldenstrom's Macroglobulinemia:A systematic review and meta-analysis. Am J Hematol 97:942-950, 2022.
PubMed
23) Abeykoon JP, Kumar S, Castillo JJ, et al:Bendamustine rituximab(BR) versus ibrutinib(Ibr) as primary therapy for Waldenstrom macroglobulinemia(WM):An international collaborative study. J Clin Oncol 16(Suppl):7566, 2022.
 
24) Deodato M, Frustaci AM, Zamprogna G, et al:Should Patients with Waldenstrom Macroglobulinemia Receive a BTK Inhibitor as Frontline Therapy? Hemato 3:689-703, 2022.
 
25) Mato AR, Shah NN, Jurczak W, et al:Pirtobrutinib in relapsed or refractory B-cell malignancies(BRUIN):a phase 1/2 study. Lancet 397:892-901, 2021.
 
26) Castillo JJ, Allan JN, Siddiqi T, et al:Venetoclax in Previously Treated Waldenstrom Macroglobulinemia. J Clin Oncol 40:63-71, 2022.
PubMed
27) Treon SP, Buske C, Thomas S, et al:Preliminary Clinical Response Data from a Phase 1b Study of Mavorixafor in Combination with Ibrutinib in Patients with Waldenstrom's Macroglobulinemia with MYD88 and CXCR4 Mutations. Blood 138(Suppl 1):1362, 2021.
 
28) Castillo JJ, Itchaki G, Paludo J, et al:Ibrutinib for the treatment of Bing-Neel syndrome:a multicenter study. Blood 133:299-305, 2019.
PubMed
29) Saburi M, Saburi Y, Kawano K, et al:Successful treatment with tirabrutinib for relapsed lymphoplasmacytic lymphoma complicated by Bing-Neel syndrome. Int J Hematol 115:585-589, 2022.
PubMed
30) Oyama T, Taoka K, Chiba A, et al:Bing-Neel Syndrome Successfully Treated with Tirabrutinib. Intern Med 61:3575-3579, 2022.
PubMed
31) Sekiguchi N:The Impact of Tirabrutinib Monotherapy for Bing-Neel Syndrome in Waldenstrom's Macroglobulinemia. Intern Med 61:3473-3474, 2022.
PubMed
P.231 掲載の参考文献
1) Alaggio R, Amador C, Anagnostopoulos I, et al:The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours:Lymphoid Neoplasms. Leukemia 36:1720-1748, 2022.
PubMed
2) Cerhan JR, Habermann TM:Epidemiology of Marginal Zone Lymphoma. Ann Lymphoma. 5:1, 2021(DOI:10.21037/aol-20-28).
 
3) Zucca E, Bertoni F, Vannata B, et al:Emerging role of infectious etiologies in the pathogenesis of marginal zone B-cell lymphomas. Clin Cancer Res 20:5207-5216, 2014.
 
4) Rossi D, Bertoni F, Zucca E:Marginal-Zone Lymphomas. N Engl J Med 386:568-581, 2022.
PubMed
5) Thieblemont C, Cascione L, Conconi A, et al:A MALT lymphoma prognostic index. Blood 130:1409-1417, 2017.
PubMed
6) Conconi A, Thieblemont C, Cascione L, et al:Early progression of disease predicts shorter survival in MALT lymphoma patients receiving systemic treatment. Haematologica 105:2592-2597, 2020.
PubMed
7) Zucca E, Arcaini L, Buske C, et al:Marginal zone lymphomas:ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 31:17-29, 2020.
 
8) National Comprehensive Cancer Network:B-cell lymphomas(NCCN guidelines version 5. 2022). 2022.(https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf)
 
9) Wirth A, Gospodarowicz M, Aleman BM, et al:Long-term outcome for gastric marginal zone lymphoma treated with radiotherapy:a retrospective, multi-centre, International Extranodal Lymphoma Study Group study. Ann Oncol 24:1344-1351, 2013.
 
10) Arcaini L, Besson C, Frigeni M, et al:Interferon-free antiviral treatment in B-cell lymphoprolifera-tive disorders associated with hepatitis C virus infection. Blood 128:2527-2532, 2016.
 
11) Wirth A, Mikhaeel NG, Aleman BMP, et al:Involved Site Radiation Therapy in Adult Lymphomas:An Overview of International Lymphoma Radiation Oncology Group Guidelines. Int J Radiat Oncol Biol Phys 107:909-933, 2020.
PubMed
12) Ardeshna KM, Smith P, Norton A, et al:Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma:a randomised controlled trial. Lancet 362:516-522, 2003.
PubMed
13) Rummel MJ, Niederle N, Maschmeyer G, et al:Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas:an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381:1203-1210, 2013.
PubMed
14) Zucca E, Conconi A, Martinelli G, et al:Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma:Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy. J Clin Oncol 35:1905-1912, 2017.
PubMed
P.236 掲載の参考文献
1) Swerdlow SH, Campo E, Harris NL, et al(ed):WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed, IARC, Lyon, 2008.
 
2) Nakamura S, Ponzoni M:Marginal zone B-cell lymphoma:lessons from Western and Eastern diagnostic approaches. Pathology 52:15-29, 2020.
PubMed
3) Alderuccio JP, Kahl BS:Current Treatments in Marginal Zone Lymphoma. Oncology(Williston Park) 36:206-215, 2022.
PubMed
4) Luminari S, Merli M, Rattotti S, et al:Early progression as a predictor of survival in marginal zone lymphomas:an analysis from the FIL-NF10 study. Blood 134:798-801, 2019.
PubMed
5) Zucca E, Arcaini L, Buske C, et al:Marginal zone lymphomas:ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 31:17-29, 2020.
 
6) Armand M, Besson C, Hermine O, et al:Hepatitis C virus-associated marginal zone lymphoma. Best Pract Res Clin Haematol 30:41-49, 2017.
PubMed
7) Rossi D, Bertoni F, Zucca E:Marginal-Zone Lymphomas. N Engl J Med 386:568-581, 2022.
PubMed
8) Kalpadakis C, Pangalis GA, Sachanas S, et al:Rituximab monotherapy in splenic marginal zone lymphoma:prolonged responses and potential benefit from maintenance. Blood 132:666-670, 2018.
PubMed
9) Iannitto E, Bellei M, Amorim S, et al:Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma:results from the phase II BRISMA/IELSG36 study. Br J Haematol 183:755-765, 2018.
PubMed
10) Salar A, Domingo-Domenech E, Panizo C, et al:Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma. Blood 130:1772-1774, 2017.
PubMed
11) Rummel MJ, Niederle N, Maschmeyer G, et al:Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas:an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381:1203-1210, 2013.
PubMed
12) Walewski J, Paszkiewicz-Kozik E, Michalski W, et al:First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4. Br J Haematol 188:898-906, 2020.
 
13) Herold M, Hoster E, Janssens A, et al:Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial. Hemasphere 6:e699, 2022.
PubMed
14) Leonard JP, Trneny M, Izutsu K, et al:AUGMENT:A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma. J Clin Oncol 37:1188-1199, 2019.
PubMed
15) Cheson BD, Chua N, Mayer J, et al:Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study. J Clin Oncol 36:2259-2266, 2018.
PubMed
16) Conconi A, Thieblemont C, Cascione L, et al:Early progression of disease predicts shorter survival in MALT lymphoma patients receiving systemic treatment. Haematologica 105:2592-2597, 2020.
PubMed
P.243 掲載の参考文献
1) Batlevi CL, Sha F, Alperovich A, et al:Follicular lymphoma in the modern era:survival, treatment outcomes, and identification of high-risk subgroups. Blood Cancer J 10:74, 2020.
PubMed
2) Sarkozy C, Maurer MJ, Link BK, et al:Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era:A Pooled Analysis of French and US Cohorts. J Clin Oncol 37:144-152, 2019.
 
3) Casulo C, Byrtek M, Dawson KL, et al:Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death:An Analysis From the National LymphoCare Study. J Clin Oncol 33:2516-2522, 2015.
PubMed
4) Huet S, Tesson B, Jais JP, et al:A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma:a retrospective training and validation analysis in three international cohorts. Lancet Oncol 19:549-561, 2018.
 
5) Luminari S, Ferrari A, Manni M, et al:Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma. J Clin Oncol 36:689-696, 2018.
PubMed
6) Rummel MJ, Niederle N, Maschmeyer G, et al:Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas:an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381:1203-1210, 2013.
PubMed
7) Salles G, Seymour JF, Offner F, et al:Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy(PRIMA):a phase 3, randomised controlled trial. Lancet 377:42-51, 2011.
 
8) Marcus R, Davies A, Ando K, et al:Obinutuzumab for the First-Line Treatment of Follicula Lymphoma. N Engl J Med 377:1331-1344, 2017.
 
9) Fujino T, Maruyama D, Maeshima AM, et al:The outcome of watchful waiting in patients with previously treated follicular lymphoma. Cancer Med 11:2106-2116, 2022.
PubMed
10) Sehn LH, Chua N, Mayer J, et al:Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma(GADOLIN):a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol 17:1081-1093, 2016.
PubMed
11) Leonard JP, Trneny M, Izutsu K, et al:AUGMENT:A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma. J Clin Oncol 37:1188-1199, 2019.
PubMed
12) Morschhauser F, Tilly H, Chaidos A, et al:Tazemetostat for patients with relapsed or refractory follicular lymphoma:an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol 21:1433-1442, 2020.
PubMed
13) Fowler NH, Dickinson M, Dreyling M, et al:Tisagenlecleucel in adult relapsed or refractory follicular lymphoma:the phase 2 ELARA trial. Nat Med 28:325-332, 2022.
 
14) Budde LE, Sehn LH, Matasar M, et al:Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma:a single-arm, multicentre, phase 2 study. Lancet Oncol 23:1055-1065, 2022.
 
15) Richardson NC, Kasamon Y, Pazdur R, et al:The saga of PI3K inhibitors in haematological malignancies:survival is the ultimate safety endpoint. Lancet Oncol 23:563-566, 2022.
PubMed
P.249 掲載の参考文献
1) Swerdlow SH, Campo E, Harris NL, et al:WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues(Revised 4th edition), WHO, Lyon, 2017.
 
2) Alaggio R, Amador C, Anagnostopoulos I, et al:The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours:Lymphoid Neoplasms. Leukemia 36:1720-1748, 2022.
PubMed
3) 日本血液学会:造血器腫瘍診療ガイドライン2018年版補訂版, 2020.
 
4) Armitage JO, Longo DL:Mantle-Cell Lymphoma. N Engl J Med 386:2495-2506, 2022.
PubMed
5) Ferrero S, Grimaldi D, Dreyling M, et al:Tailored treatment in mantle cell lymphoma. Ann Lymphoma 4:12, 2020.
 
6) Eyre TA, Cheah CY, Wang ML:Therapeutic options for relapsed/refractory mantle cell lymphoma. Blood 139:666-677, 2022.
PubMed
7) Ferrero S, Rossi D, Rinaldi A, et al:KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy:a FIL study. Haematologica 105:1604-1612, 2020.
PubMed
8) Leitch HA, Gascoyne RD, Chhanabhai M, et al:Limited-stage mantle-cell lymphoma. Ann Oncol 14:1555-1561, 2003.
PubMed
9) Schulz H, Bohlius JF, Trelle S, et al:Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma:a systematic review and meta-analysis. J Natl Cancer Inst 99:706-714, 2007.
PubMed
10) Geisler CH, Kolstad A, Laurell A, et al:Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue:a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 112:2687-2693, 2008.
 
11) Chihara D, Cheah CY, Westin JR, et al:Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma:15-year follow-up of a phase II study from the MD Anderson Cancer Center. Br J Haematol 172:80-88, 2016.
 
12) Chen RW, Li H, Bernstein SH, et al:RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL:results of SWOG Study S1106. Br J Haematol 176:759-769, 2017.
 
13) Merryman RW, Edwin N, Redd R, et al:Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. Blood Adv 4:858-867, 2020.
PubMed
14) Zoellner AK, Unterhalt M, Stilgenbauer S, et al:Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission:a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol 8:e648-e657, 2021.
PubMed
15) Le Gouill S, Thieblemont C, Oberic L, et al:Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma. N Engl J Med 377:1250-1260, 2017.
PubMed
16) Kluin-Nelemans HC, Hoster E, Hermine O, et al:Treatment of Older Patients With Mantle Cell Lymphoma(MCL):Long-Term Follow-Up of the Randomized European MCL Elderly Trial. J Clin Oncol 38:248-256, 2020.
 
17) Robak T, Jin J, Pylypenko H, et al:Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone(VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone(R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma:final overall survival results of a randomised, open-label, phase 3 study. Lancet Oncol 19:1449-1458, 2018.
 
18) Flinn IW, van der Jagt R, Kahl BS, et al:Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL:the BRIGHT study. Blood 123:2944-2952, 2014.
 
19) Wang ML, Jurczak W, Jerkeman M, et al:Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma. N Engl J Med 386:2482-2494, 2022.
PubMed
20) Visco C, Di Rocco A, Evangelista A, et al:Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma:results from the MANTLE-FIRST study. Leukemia 35:787-795, 2021.
PubMed
21) Munshi PN, Hamadani M, Kumar A, et al:ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma. Bone Marrow Transplant 56:2911-2921, 2021.
PubMed
P.256 掲載の参考文献
1) Coiffier B, Lepage E, Briere J, et al:CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242, 2002.
PubMed
2) Pfreundschuh M, Trumper L, Osterborg A, et al:CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large B-cell lymphoma:a randomised controlled trial by the MabThera International Trial(MInT) Group. Lancet Oncol 7:379-391, 2006.
PubMed
3) Pfreundschuh M, Schubert J, Ziepert M, et al:Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas:a randomised controlled trial(RICOVER-60). Lancet Oncol 9:105-116, 2008.
PubMed
4) Vitolo U, Trneny M, Belada D, et al:Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma. J Clin Oncol 35:3529-3537, 2017.
 
5) Sehn LH, Salles G:Diffuse Large B-Cell Lymphoma. N Engl J Med 384:842-858, 2021.
PubMed
6) Stephens DM, Li H, LeBlanc ML, et al:Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma:Final and Long-Term Analysis of Southwest Oncology Group Study S8736. J Clin Oncol 34:2997-3004, 2016.
 
7) Poeschel V, Held G, Ziepert M, et al:Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis(FLYER):a randomised, phase 3, non-inferiority trial. Lancet 394:2271-2281, 2019.
 
8) Persky DO, Li H, Stephens DM, et al:Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma:Results of Intergroup National Clinical Trials Network Study S1001. J Clin Oncol 38:3003-3011, 2020.
PubMed
9) Lamy T, Damaj G, Soubeyran P, et al:R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma. Blood 131:174-181, 2018.
PubMed
10) Tilly H, Morschhauser F, Sehn LH, et al:Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. N Engl J Med 386:351-363, 2022.
PubMed
11) Roschewski M, Staudt LM, Wilson WH:Diffuse large B-cell lymphoma-treatment approaches in the molecular era. Nat Rev Clin Oncol 11:12-23, 2014.
PubMed
12) Younes A, Sehn LH, Johnson P, et al:Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma. J Clin Oncol 37:1285-1295, 2019.
PubMed
13) Nowakowski GS, Chiappella A, Gascoyne RD, et al:ROBUST:A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma. J Clin Oncol 39:1317-1328, 2021.
 
14) Schmitz R, Wright GW, Huang DW, et al:Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. N Engl J Med 378:1396-1407, 2018.
PubMed
15) Sehn LH, Herrera AF, Flowers CR, et al:Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. J Clin Oncol 38:155-165, 2020.
 
P.263 掲載の参考文献
1) Kluin PM, Harris NL, Stein H, et al:High-grade B-cell lymphoma. In:WHO Classfication of Tumours of Hematopoietic and Lymphoid Tissues, Revised Fourth Edition(ed by Swerdlow SH, Campo E, Harris NL, et al), p335-341, IARC Press, Lyon, 2017.
 
2) Kluin PM, Harris NL, Stein H, et al:B-cell lymphoma, unclassfiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. In:WHO Classfication of Tumours of Hematopoietic and Lymphoid Tissues, Fourth Edition(ed by Swerdlow SH, Campo E, Harris NL, et al), p265-266, IARC Press, Lyon, 2008.
 
3) Alaggio R, Amador C, Anagnostopoulos I, et al:The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours:Lymphoid Neoplasms. Leukemia 36:1720-1748, 2022.
PubMed
4) Campo E, Jaffe ES, Cook JR, et al:The International Consensus Classification of Mature Lymphoid Neoplasms:a report from the Clinical Advisory Committee. Blood 140:1229-1253, 2022.
PubMed
5) Oki Y, Noorani M, Lin P, et al:Double hit lymphoma:the MD Anderson Cancer Center clinical experience. Br J Haematol 166:891-901, 2014.
 
6) Petrich AM, Gandhi M, Jovanovic B, et al:Impact of induction regimen and stem cell transplantationon outcomes in double-hit lymphoma:a multicenter retrospective analysis. Blood 124:2354-2361, 2014.
PubMed
7) Landsburg DJ, Falkiewicz MK, Maly J, et al:Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission. J Clin Oncol 35:2260-2267, 2017.
PubMed
8) Olszewski AJ, Kurt H, Evens AM:Defining and treating high-grade B-cell lymphoma, NOS. Blood 140:943-954, 2022.
PubMed
9) Abramson JS, Ruppert AS, Giri S, et al:Randomized phase II/III study of DA-EPOCH-R +/- venetoclax in previously untreated double hit lymphoma:initial results from Alliance A051701, Blood 138(Suppl):523, 2021.
 
10) Bishop MR, Dickinson M, Purtill D, et al:Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. N Engl J Med 386:629-639, 2022.
PubMed
11) Kamdar M, Solomon SR, Arnason J, et al:Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma(TRANSFORM):results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet 399:2294-2308, 2022.
PubMed
12) Locke FL, Miklos DB, Jacobson CA, et al:Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. N Engl J Med 386:640-654, 2022.
 
13) Neelapu SS, Dickinson M, Munoz J, et al:Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma:the phase 2 ZUMA-12 trial. Nat Med 28:735-742, 2022.
 
14) Ennishi D, Jiang A, Boyle M, et al:Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. J Clin Oncol 37:190-201, 2019.
PubMed
15) Sha C, Barrans S, Cucco F, et al:Molecular High-Grade B-Cell Lymphoma:Defining a Poor-Risk Group That Requires Different Approaches to Therapy. J Clin Oncol 37:202-212, 2019.
PubMed
P.268 掲載の参考文献
1) Rudiger T, Jaffe ES, Delsol G, et al:Workshop report on Hodgkin's disease and related diseases('grey zone' lymphoma). Ann Oncol 9(Suppl 5):S31-38, 1998.
 
2) Swerdlow S, Campo E, Harris N, et al(ed):WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed, IARC Press, Lyon, 2008.
 
3) Wilson WH, Pittaluga S, Nicolae A, et al:A prospective study of mediastinal gray-zone lymphoma. Blood 124:1563-1569, 2014.
PubMed
4) Evens AM, Kanakry JA, Sehn LH, et al:Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma:characteristics, outcomes, and prognostication among a large multicenter cohort. Am J Hematol 90:778-783, 2015.
PubMed
5) Hasserjian R, Le Beau M, List A, et al:WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. revised 4th ed, IARC, Lyon, 2017.
 
6) Tanaka Y, Maeshima AM, Nomoto J, et al:Expression pattern of PD-L1 and PD-L2 in classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, and gray zone lymphoma. Eur J Haematol 100:511-517, 2018.
 
7) Sarkozy C, Chong L, Takata K, et al:Gene expression profiling of gray zone lymphoma. Blood Adv 4:2523-2535, 2020.
PubMed
8) Pilichowska M, Pittaluga S, Ferry JA, et al:Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL. Blood Adv 1:2600-2609, 2017.
PubMed
9) Sarkozy C, Copie-Bergman C, Damotte D, et al:Gray-zone Lymphoma Between cHL and Large B-Cell Lymphoma:A Histopathologic Series From the LYSA. Am J Surg Pathol 43:341-351, 2019.
 
10) Green MR, Monti S, Rodig SJ, et al:Integrative analysis reveals selective 9p24. 1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 116:3268-3277, 2010.
 
11) Kritharis A, Pilichowska M, Evens AM:How I manage patients with grey zone lymphoma. Br J Haematol 174:345-350, 2016.
 
12) Eberle FC, Rodriguez-Canales J, Wei L, et al:Methylation profiling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical Hodgkin's lymphoma and primary mediastinal large B-cell lymphoma. Haematologica 96:558-566, 2011.
 
13) Sarkozy C, Hung SS, Chavez EA, et al:Mutational landscape of gray zone lymphoma. Blood 137:1765-1776, 2021.
PubMed
14) Armand P, Rodig S, Melnichenko V, et al:Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma. J Clin Oncol 37:3291-3299, 2019.
PubMed
15) Armand P, Engert A, Younes A, et al:Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation:Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. J Clin Oncol 36:1428-1439, 2018.
 
16) Melani C, Major A, Schowinsky J, et al:PD-1 Blockade in Mediastinal Gray-Zone Lymphoma. N Engl J Med 377:89-91, 2017.
PubMed
17) Jacobsen ED, Sharman JP, Oki Y, et al:Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood 125:1394-1402, 2015.
 
P.273 掲載の参考文献
1) Swerdlow SH, Campo E, Harris NL, et al:WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon, 2008.
 
2) Savage KJ:Primary mediastinal large B-cell lymphoma. Blood 140:955-970, 2022.
 
3) Barth TF, Leithauser F, Joos S, et al:Mediastinal(thymic) large B-cell lymphoma:where do we stand? Lancet Oncol 3:229-234, 2002.
 
4) Cazals-Hatem D, Lepage E, Brice P, et al:Primary mediastinal large B-cell lymphoma. A clinicopathologic study of 141 cases compared with 916 nonmediastinal large B-cell lymphomas, a GELA("Groupe d'Etude des Lymphomes de l'Adulte") study. Am J Surg Pathol 20:877-888, 1996.
 
5) Lazzarino M, Orlandi E, Paulli M, et al:Treatment outcome and prognostic factors for primary mediastinal(thymic) B-cell lymphoma:a multicenter study of 106 patients. J Clin Oncol 15:1646-1653, 1997.
PubMed
6) Sarkozy C, Hung SS, Chavez EA, et al:Mutational landscape of gray zone lymphoma. Blood 137:1765-1776, 2021.
PubMed
7) Gunawardana J, Chan FC, Telenius A, et al:Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma. Nat Genet 46:329-335, 2014.
PubMed
8) Steidl C, Shah SP, Woolcock BW, et al:MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature 471:377-381, 2011.
PubMed
9) Mottok A, Wright G, Rosenwald A, et al:Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens. Blood 132:2401-2405, 2018.
 
10) Duns G, Vigano E, Ennishi D, et al:Characterization of DLBCL with a PMBL gene expression signature. Blood 138:136-148, 2021.
PubMed
11) Paulli M, Strater J, Gianelli U, et al:Mediastinal B-cell lymphoma:a study of its histomorphologic spectrum based on 109 cases. Hum Pathol 30:178-187, 1999.
PubMed
12) Pileri SA, Gaidano G, Zinzani PL, et al:Primary mediastinal B-cell lymphoma:high frequency of BCL-6 mutations and consistent expression of the transcription factors OCT-2, BOB. 1, and PU. 1 in the absence of immunoglobulins. Am J Pathol 162:243-253, 2003.
PubMed
13) Pileri SA, Zinzani PL, Gaidano G, et al:Pathobiology of primary mediastinal B-cell lymphoma. Leuk Lymphoma 44(Suppl 3):S21-S26, 2003.
 
14) Traverse-Glehen A, Pittaluga S, Gaulard P, et al:Mediastinal gray zone lymphoma:the missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma. Am J Surg Pathol 29:1411-1421, 2005.
 
15) Rosenwald A, Wright G, Leroy K, et al:Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 198:851-862, 2003.
PubMed
16) Eberle FC, Rodriguez-Canales J, Wei L, et al:Methylation profiling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical Hodgkin's lymphoma and primary mediastinal large B-cell lymphoma. Haematologica 96:558-566, 2011.
 
17) Savage KJ, Monti S, Kutok JL, et al:The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 102:3871-3879, 2003.
 
18) Gentry M, Bodo J, Durkin L, et al:Performance of a Commercially Available MAL Antibody in the Diagnosis of Primary Mediastinal Large B-Cell Lymphoma. Am J Surg Pathol 41:189-194, 2017.
 
19) Dunleavy K, Pittaluga S, Maeda LS, et al:Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med 368:1408-1416, 2013.
PubMed
20) Shah NN, Szabo A, Huntington SF, et al:R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma:a multi-centre analysis. Br J Haematol 180:534-544, 2018.
PubMed
21) Malenda A, Kolkowska-Lesniak A, Pula B, et al:Outcomes of treatment with dose-adjusted EPOCH-R or R-CHOP in primary mediastinal large B-cell lymphoma. Eur J Haematol 104:59-66, 2020.
PubMed
22) Bartlett NL, Wilson WH, Jung SH, et al:Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma:Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. J Clin Oncol 37:1790-1799, 2019.
 
23) Aoki T, Shimada K, Suzuki R, et al:High-dose chemotherapy followed by autologous stem cell transplantation for relapsed/refractory primary mediastinal large B-cell lymphoma. Blood Cancer J 5:e372, 2015.
 
24) Zinzani PL, Pellegrini C, Chiappella A, et al:Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma:results from a phase 2 clinical trial. Blood 129:2328-2330, 2017.
 
25) Kim SJ, Yoon DH, Kang HJ, et al:Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma. BMC Cancer 19:1080, 2019.
PubMed
26) Zinzani PL, Ribrag V, Moskowitz CH, et al:Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma. Blood 130:267-270, 2017.
 
27) Armand P, Rodig S, Melnichenko V, et al:Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma. J Clin Oncol 37:3291-3299, 2019.
PubMed
28) Zinzani PL, Santoro A, Gritti G, et al:Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma:Efficacy and Safety From the Phase II CheckMate 436 Study. J Clin Oncol 37:3081-3089, 2019
 
P.281 掲載の参考文献
1) Alaggio R, Amador C, Anagnostopoulos I, et al:The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours:Lymphoid Neoplasms. Leukemia 36:1720-1748, 2022.
PubMed
2) Geer M, Roberts E, Shango M, et al:Multicentre retrospective study of intravascular large B-cell lymphoma treated at academic institutions within the United States. Br J Haematol 186:255-262, 2019.
 
3) Shimada K, Kinoshita T, Naoe T, et al:Presentation and management of intravascular large B-cell lymphoma. Lancet Oncol 10:895-902, 2009.
 
4) Enzan N, Kitadate A, Tanaka A, et al:Incisional random skin biopsy, not punch biopsy, is an appropriate method for diagnosis of intravascular large B-cell lymphoma:a clinicopathological study of 25 patients. Br J Dermatol 181:200-201, 2019.
 
5) Matsue K, Abe Y, Kitadate A, et al:Sensitivity and specificity of incisional random skin biopsy for diagnosis of intravascular large B-cell lymphoma. Blood 133:1257-1259, 2019.
 
6) Abe Y, Narita K, Kobayashi H, et al:Clinical value of abnormal findings on brain magnetic resonance imaging in patients with intravascular large B-cell lymphoma. Ann Hematol 97:2345-2352, 2018.
 
7) Shimada K, Matsue K, Yamamoto K, et al:Retrospective analysis of intravascular large B-cell lymphoma treated with rituximab-containing chemotherapy as reported by the IVL study group in Japan. J Clin Oncol 26:3189-3195, 2008.
 
8) Shimada K, Murase T, Matsue K, et al:Central nervous system involvement in intravascular large B-cell lymphoma:a retrospective analysis of 109 patients. Cancer Sci 101:1480-1486, 2010.
 
9) Shimada K, Yamaguchi M, Atsuta Y, et al:Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma(PRIMEUR-IVL):a multicentre, single-arm, phase 2 trial. Lancet Oncol 21:593-602, 2020.
 
10) Kato K, Mori T, Kim SW, et al:Outcome of patients receiving consolidative autologous peripheral blood stem cell transplantation in the frontline treatment of intravascular large B-cell lymphoma:Adult Lymphoma Working Group of the Japan Society for Hematopoietic Cell Transplantation. Bone Marrow Transplant 54:1515-1517, 2019.
 
11) Hill BT, Roth CJ, Kositsky R, et al:Impact of Molecular Features of Diffuse Large B-Cell Lymphoma on Treatment Outcomes with Anti-CD19 Chimeric Antigen Receptor(CAR) T-Cell Therapy Blood 138(Suppl 1):165, 2021.
 
12) Shimada K, Yoshida K, Suzuki Y, et al:Frequent genetic alterations in immune checkpoint-related genes in intravascular large B-cell lymphoma. Blood 137:1491-1502, 2021.
 
13) Tilly H, Morschhauser F, Sehn LH, et al:Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. N Engl J Med 386:351-363, 2022.
PubMed
P.287 掲載の参考文献
1) Bailly J, Jenkins N, Chetty D, et al:Plasmablastic lymphoma:An update. Int J Lab Hematol 44(Suppl 1):54-63, 2022.
 
2) Castillo JJ, Bibas M, Miranda RN:The biology and treatment of plasmablastic lymphoma. Blood 125:2323-2330, 2015.
PubMed
3) Alaggio R, Amador C, Anagnostopoulos I, et al:The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours:Lymphoid Neoplasms. Leukemia 36:1720-1748, 2022.
PubMed
4) Zarifi C, Deutsch S, Dullet N, et al:An enlarging pacemaker pocket:A case report of a plasmablastic lymphoma arising as a primary tumor around a cardiac pacemaker and systematic literature review of various malignancies arising at the pacemaker pocket. J Cardiol Cases 17:41-43, 2018.
PubMed
5) Frontzek F, Staiger AM, Zapukhlyak M, et al:Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma. Nat Commun 12:5183, 2021.
PubMed
6) Garcia-Reyero J, Martinez Magunacelaya N, Gonzalez de Villambrosia S, et al:Genetic lesions in MYC and STAT3 drive oncogenic transcription factor overexpression in plasmablastic lymphoma. Haematologica 106:1120-1128, 2021.
PubMed
7) Zhou T, Cheng J, Karrs J, et al:Clinicopathologic and Molecular Characterization of Epstein-Barr Virus-positive Plasmacytoma. Am J Surg Pathol 46:1364-1379, 2022.
 
8) Mori H, Fukatsu M, Ohkawara H, et al:Heterogeneity in the diagnosis of plasmablastic lymphoma, plasmablastic myeloma, and plasmablastic neoplasm:a scoping review. Int J Hematol 114:639-652, 2021.
PubMed
9) Makady NF, Ramzy D, Ghaly R, et al:The Emerging Treatment Options of Plasmablastic Lymphoma:Analysis of 173 Individual Patient Outcomes. Clin Lymphoma Myeloma Leuk 21:e255-e263, 2021.
PubMed
10) Castillo JJ, Guerrero-Garcia T, Baldini F, et al:Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma. Br J Haematol 184:679-682, 2019.
PubMed
11) Jessa R, Chien N, Villa D, et al:Clinicopathological characteristics and long-term outcomes of plasmablastic lymphoma in British Columbia. Br J Haematol 199:230-238, 2022.
PubMed
12) Cattaneo C, Finel H, McQuaker G, et al:Autologous hematopoietic stem cell transplantation for plasmablastic lymphoma:the European Society for Blood and Marrow Transplantation experience. Biol Blood Marrow Transplant 21:1146-1147, 2015.
PubMed
13) Ryu YK, Ricker EC, Soderquist CR, et al:Targeting CD38 with Daratumumab Plus Chemotherapy for Patients with Advanced-Stage Plasmablastoid Large B-Cell Lymphoma. J Clin Med 11:49282022.
 
14) Delecluse HJ, Anagnostopoulos I, Dallenbach F, et al:Plasmablastic lymphomas of the oral cavity:a new entity associated with the human immunodeficiency virus infection. Blood 89:1413-1420, 1997.
PubMed
15) Vega F, Chang CC, Medeiros LJ, et al:Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles. Mod Pathol 18:806-815, 2005.
PubMed
16) Alaggio R, Amador C, Anagnostopoulos I, et al:The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours:Lymphoid Neoplasms. Leukemia 36:1720-1748, 2022.
PubMed
17) Harris NL, Jaffe ES, Stein H, et al:A revised European-American classification of lymphoid neoplasms:a proposal from the International Lymphoma Study Group. Blood 84:1361-1392, 1994.
 
18) Green TL, Eversole LR:Oral lymphomas in HIV-infected patients:association with Epstein-Barr virus DNA. Oral Surg Oral Med Oral Pathol 67:437-442, 1989.
PubMed
19) Kochling G, Ochs A, Hauke G, et al:Plasmablastic immunoglobulin-secreting lymphoma. Report of acase and a glimpse at the prognosis. Klin Wochenschr 66:990-994, 1988.
 
P.292 掲載の参考文献
1) Swerdlow SH, Campo E, Harris NL, et al(ed):WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th Edition, Volume 2, The International Agency for Research on Cancer, Lyon, 2017.
 
2) Cesarman E, Chang Y, Moore PS, et al:Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 332:1186-1191, 1995.
PubMed
3) Kaji D, Ota Y, Sato Y, et al:Primary human herpesvirus 8-negative effusion-based lymphoma:a large B-cell lymphoma with favorable prognosis. Blood Adv 4:4442-4450, 2020.
 
4) Katano H, Sata T:Human herpesvirus 8 virology, epidemiology and related diseases. Jpn J Infect Dis 53:137-155, 2000.
PubMed
5) Said JW, Tasaka T, Takeuchi S, et al:Primary effusion lymphoma in women:report of two cases of Kaposi's sarcoma herpes virus-associated effusion-based lymphoma in human immunodeficiency virus-negative women. Blood 88:3124-3128, 1996.
PubMed
6) Klein U, Gloghini A, Gaidano G, et al:Gene expression profile analysis of AIDS-related primary effusion lymphoma(PEL) suggests a plasmablastic derivation and identifies PEL-specific transcripts. Blood 101:4115-4121, 2003.
PubMed
7) Tolani B, Gopalakrishnan R, Punj V, et al:Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors. Oncogene 33:2928-2937, 2014.
PubMed
8) Gathers DA, Galloway E, Kelemen K, et al:Primary Effusion Lymphoma:A Clinicopathologic Perspective. Cancers(Basel) 14:722, 2022.
PubMed
9) Shimada K, Hayakawa F, Kiyoi H:Biology and management of primary effusion lymphoma. Blood 132:1879-1888, 2018.
PubMed
10) Won JH, Han SH, Bae SB, et al:Successful eradication of relapsed primary effusion lymphoma with high-dose chemotherapy and autologous stem cell transplantation in a patient seronegative for human immunodeficiency virus. Int J Hematol 83:328-330, 2006.
 
11) Bryant A, Milliken S:Successful reduced intensity conditioning allogeneic HSCT for HIV-related primary effusion lymphoma. Biol Blood Marrow Transplant 14:601-602, 2008.
PubMed
12) Shah NN, Singavi AK, Harrington A:Daratumumab in Primary Effusion Lymphoma:N Engl J Med 379:689-690, 2018.
PubMed
13) Lurain K, Ramaswami R, Widell A, et al:Phase I/II Study of Lenalidomide Combined with DA-EPOCH and Rituximab(DA-EPOCH-R2) in Primary Effusion Lymphoma in Patients with or without HIV. Blood 134(Suppl 1):4096, 2019.
 
P.296 掲載の参考文献
1) Boshoff C, Chang Y:Kaposi's sarcoma-associated herpesvirus:a new DNA tumor virus. Annu Rev Med 52:453-470, 2001.
PubMed
2) Simpson GR, Schulz TF, Whitby D, et al:Prevalence of Kaposi's sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen. Lancet 348:1133-1138, 1996.
PubMed
3) Alaggio R, Amador C, Anagnostopoulos I, et al:The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours:Lymphoid Neoplasms. Leukemia 36:1720-1748, 2022.
PubMed
4) Foster WR, Bischin A, Dorer R, et al:Human Herpesvirus Type 8-associated Large B-cell Lymphoma:A Nonserous Extracavitary Variant of Primary Effusion Lymphoma in an HIV-infected Man:A Case Report and Review of the Literature. Clin Lymphoma Myeloma Leuk 16:311-321, 2016.
 
5) Dupin N, Diss TL, Kellam P, et al:HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood 95:1406-1412, 2000.
PubMed
6) Oksenhendler E, Boulanger E, Galicier L, et al:High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease. Blood 99:2331-2336, 2002.
PubMed
7) Ghoneima A, Cooke J, Shaw E, et al:Human herpes virus 8-positive germinotropic lymphoprolifera-tive disorder:first case diagnosed in the UK, literature review and discussion of treatment options. BMJ Case Rep 13:e231640, 2020.
PubMed
8) Zanelli M, Zizzo M, Bisagni A, et al:Germinotropic lymphoproliferative disorder:a systematic review. Ann Hematol 99:2243-2253, 2020.
PubMed
9) Du MQ, Diss TC, Liu H, et al:KSHV-and EBV-associated germinotropic lymphoproliferative disorder. Blood 100:3415-3418, 2002.
PubMed
10) Said J IP, Campo E, Harris NL:HHV8-associated lymphoproliferative disorders. In:WHO Classification of Tumours of Haematopoetic and Lymphoid Tissues, Revised 4th ed(ed by Swerdlow SH, Campo E, Harris NL et al), International Agency for Research on Cancer(IARC), Lyon, 325-329, 2017.
 
11) Suda T, Katano H, Delsol G, et al:HHV-8 infection status of AIDS-unrelated and AIDS-associated multicentric Castleman's disease. Pathol Int 51:671-679, 2001.
PubMed
12) Rehman MEU, Chattaraj A, Neupane K, et al:Efficacy and safety of regimens used for the treatment of multicentric Castleman disease:A systematic review. Eur J Haematol 109:309-320, 2022.
PubMed
13) Katano H, Sato Y, Kurata T, et al:Expression and localization of human herpesvirus 8-encoded proteins in primary effusion lymphoma, Kaposi's sarcoma, and multicentric Castleman's disease. Virology 269:335-344, 2000.
PubMed
P.302 掲載の参考文献
1) WHO Classification of Tumours, Revised 4th ed, Vol 2, WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues(ed by Swerdlow SH, Campo E, Harris NL, et al), IARC, Lyon, 2017.
 
2) Crombie J, LaCasce A:The treatment of Burkitt lymphoma in adults. Blood 137:743-750, 2021.
PubMed
3) Katsushima H, Fukuhara N, Ichikawa S, et al:Non-biased and complete case registration of lymphoid leukemia and lymphoma for five years:a first representative index of Japan from an epidemiologically stable Miyagi Prefecture. Leuk Lymphoma 58:80-88, 2017.
 
4) Kojima Y, Hagiwara S, Uehira T, et al:Clinical outcomes of AIDS-related Burkitt lymphoma:a multi-institution retrospective survey in Japan. Jpn J Clin Oncol 44:318-323, 2014.
PubMed
5) Alaggio R, Amador C, Anagnostopoulos I, et al:The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours:Lymphoid Neoplasms. Leukemia 36:1720-1748, 2022.
PubMed
6) Magrath I, Adde M, Shad A, et al:Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 14:925-934, 1996.
PubMed
7) Mead GM, Sydes MR, Walewski J, et al:An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma:results of United Kingdom Lymphoma Group LY06 study. Ann Oncol 13:1264-1274, 2002.
PubMed
8) Mead GM, Barrans SL, Qian W, et al:A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria(MRC/NCRI LY10 trial). Blood 112:2248-2260, 2008.
PubMed
9) Maruyama D, Watanabe T, Maeshima AM, et al:Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate(CODOX-M)/ifosfamide, etoposide, and cytarabine(IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma(BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL. Int J Hematol 92:732-743, 2010.
PubMed
10) Zhu KY, Song KW, Connors JM, et al:Excellent real-world outcomes of adults with Burkitt lymphoma treated with CODOX-M/IVAC plus or minus rituximab. Br J Haematol 181:782-790, 2018.
PubMed
11) Thomas DA, Faderl S, O'Brien S, et al:Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 106:1569-1580, 2006.
PubMed
12) Dunleavy K, Pittaluga S, Shovlin M, et al:Low-intensity therapy in adults with Burkitt's lymphoma. N Engl J Med 369:1915-1925, 2013.
PubMed
13) Roschewski M, Dunleavy K, Abramson JS, et al:Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma. J Clin Oncol 38:2519-2529, 2020.
PubMed
14) Zayac AS, Evens AM, Danilov A, et al:Outcomes of Burkitt lymphoma with central nervous system involvement:evidence from a large multicenter cohort study. Haematologica 106:1932-1942, 2021.
PubMed
15) Dunleavy K:Approach to the Diagnosis and Treatment of Adult Burkitt's Lymphoma. J Oncol Pract 14:665-671, 2018.
 
P.307 掲載の参考文献
1) Van Vlierberghe P, Ferrando A:The molecular basis of T cell acute lymphoblastic leukemia. J Clin Invest 122:3398-3406, 2012.
PubMed
2) Van Vlierberghe P, Pieters R, Beverloo HB, et al:Molecular-genetic insights in paediatric T-cell acute lymphoblastic leukaemia. Br J Haematol 143:153-168, 2008.
PubMed
3) Basso K, Mussolin L, Lettieri A, et al:T-cell lymphoblastic lymphoma shows differences and similarities with T-cell acute lymphoblastic leukemia by genomic and gene expression analyses. Genes Chromosomes Caner 50:1063-1075, 2011.
 
4) Burkhardt B, Hermiston ML:Lymphoblastic lymphoma in children and adolescents:review of current challenges and future opportunities. Br J Haematol 185:1158-1170, 2019.
PubMed
5) Coustan-Smith E, Mullighan CG, Onciu M, et al:Early T-cell precursor leukaemia:a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol 10:147-156, 2009.
 
6) Conter V, Valsecchi MG, Buldini B, et al:Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols:a retrospective analysis. Lancet Haematol 3:e80-e86, 2016.
 
7) Liu Y, Easton J, Shao Y, et al:The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nat Genet 49:1211-1218, 2017.
 
8) Summers RJ, Teachey DT:SOHO State of the Art Updates and Next Questions | Novel Approaches to Pediatric T-cell ALL and T-Lymphoblastic Lymphoma. Clin Lymphoma Myeloma Leuk 22:718-725, 2022.
 
9) Seki M, Kimura S, Isobe T, et al:Recurrent SPI1(PU. 1) fusions in high-risk pediatric T cell acute lymphoblastic leukemia. Nat Genet 49:1274-1281, 2017.
PubMed
10) Schrappe M, Valsecchi MG, Bartram CR, et al:Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL:results of the AIEOP-BFM-ALL 2000 study. Blood 118:2077-2084, 2011.
PubMed
11) Sato A, Hatta Y, Imai C, et al:Impact of Nelarabine, Intensive L-Asparaginase, and Protracted Intrathecal Therapy on Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia:Results from the Japanese Pediatric Leukemia/Lymphoma Study Group and the Japan Adult Leukemia Study Group. Blood 138(Suppl 1):3393, 2021.
 
12) Dunsmore KP, Winter SS, Devidas M, et al:Children's Oncology Group AALL0434:A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. J Clin Oncol 38:3282-3293, 2020.
 
13) Teachey DT, Devidas M, Wood BL, et al:Children's Oncology Group Trial AALL1231:A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma. J Clin Oncol 40:2106-2118, 2022.
 
14) Balbach ST, Makarova O, Bonn BR, et al:Proposal of a genetic classifier for risk group stratification in pediatric T-cell lymphoblastic lymphoma reveals differences from adult T-cell lymphoblastic leukemia. Leukemia 30:970-973, 2016.
PubMed
15) Sunami S, Sekimizu M, Takimoto T, et al:Prognostic Impact of Intensified Maintenance Therapy on Children With Advanced Lymphoblastic Lymphoma:A Report From the Japanese Pediatric Leukemia/Lymphoma Study Group ALB-NHL03 Study. Pediatr Blood Cancer 63:451-457, 2016.
 
P.312 掲載の参考文献
1) Herling M, Khoury JD, Washington LT, et al:A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories. Blood 104:328-335, 2004.
PubMed
2) Jain P, Aoki E, Keating M, et al:Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia(T-PLL). Ann Oncol 28:1554-1559, 2017.
 
3) Taylor AM, Metcalfe JA, Thick J, et al:Leukemia and lymphoma in ataxia telangiectasia. Blood 87:423-438, 1996.
PubMed
4) Yamasaki S, Nitta H, Kondo E, et al:Effect of allogeneic hematopoietic cell transplantation for patients with T-prolymphocytic leukemia:a retrospective study from the Adult Lymphoma Working Group of the Japan Society for hematopoietic cell transplantation. Ann Hematol 98:2213-2220, 2019.
 
5) Staber PB, Herling M, Bellido M, et al:Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia. Blood 134:1132-1143, 2019.
PubMed